

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061504 A1

(51) International Patent Classification⁷: C07D 487/04, A61K 31/4985, A61P 25/00 // (C07D 487/04, 237:00, 231:00) (C07D 487/04, 237:00, 235:00)

(21) International Application Number:
PCT/IB2004/004017

(22) International Filing Date: 6 December 2004 (06.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/529,909 16 December 2003 (16.12.2003) US

(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARPINI, Philip, Albert [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). SAKYA, Subas, Man [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agent: FULLER, Grover, E., Jr.; c/o LAWRENCE, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KH, LS, MW, MZ, NA, SD, SI, SZ, TZA, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BICYCLIC PYRIDAZINONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

WO 2005/061504 A1



(57) Abstract: Compounds of Formula (I) and (II) are described herein, as well as their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors (in particular, the CB-1 receptor) in animals.

BICYCLIC PYRIDAZINONE AS CANNABINOIS RECEPTOR LIGANDS AND USES THEREOF

FIELD OF THE INVENTION

5 The present invention relates to 2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one and 1,5-dihydro-imidazo[4,5-d]pyridazin-4-one compounds. The pyridazinone compounds are useful as cannabinoid receptor ligands, in particular as CB-1 receptor antagonists. As a result, the present invention also relates to the use of the pyridazinone compounds in treating diseases, 10 conditions and disorders modulated by cannabinoid receptor ligands including pharmaceutical compositions for such use.

BACKGROUND

Obesity is a major public health concern because of its increasing prevalence and associated health risks. Obesity and overweight are generally 15 defined by body mass index (BMI), which is correlated with total body fat and estimates the relative risk of disease. BMI is calculated by weight in kilograms divided by height in meters squared (kg/m^2). Overweight is typically defined as a BMI of 25-29.9 kg/m^2 , and obesity is typically defined as a BMI of 30 kg/m^2 . See, e.g., National Heart, Lung, and Blood Institute, Clinical Guidelines on the 20 Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, The Evidence Report, Washington, DC: U.S. Department of Health and Human Services, NIH publication no. 98-4083 (1998).

The increase in obesity is of concern because of the excessive health risks associated with obesity, including coronary heart disease, strokes, 25 hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnea, osteoarthritis, gall bladder disease, depression, and certain forms of cancer (e.g., endometrial, breast, prostate, and colon). The negative health consequences of obesity make it the second leading cause of preventable death in the United States and impart a significant economic and psychosocial 30 effect on society. See, McGinnis M, Foege WH, "Actual Causes of Death in the United States," JAMA, 270, 2207-12 (1993).

Obesity is now recognized as a chronic disease that requires treatment to reduce its associated health risks. Although weight loss is an important treatment outcome, one of the main goals of obesity management is to improve cardiovascular and metabolic values to reduce obesity-related morbidity and mortality. It has been shown that 5-10% loss of body weight can substantially improve metabolic values, such as blood glucose, blood pressure, and lipid concentrations. Hence, it is believed that a 5-10% intentional reduction in body weight may reduce morbidity and mortality.

Currently available prescription drugs for managing obesity generally reduce weight by inducing satiety or decreasing dietary fat absorption. Satiety is achieved by increasing synaptic levels of norepinephrine, serotonin, or both. For example, stimulation of serotonin receptor subtypes 1B, 1D, and 2C and 1- and 2-adrenergic receptors decreases food intake by regulating satiety. See, Bray GA, "The New Era of Drug Treatment. Pharmacologic Treatment of Obesity: Symposium Overview," Obes Res., 3(suppl 4), 415s-7s (1995). Adrenergic agents (e.g., diethylpropion, benzphetamine, phendimetrazine, mazindol, and phentermine) act by modulating central norepinephrine and dopamine receptors through the promotion of catecholamine release. Older adrenergic weight-loss drugs (e.g., amphetamine, methamphetamine, and phenmetrazine), which strongly engage in dopamine pathways, are no longer recommended because of the risk of their abuse. Fenfluramine and dexfenfluramine, both serotonergic agents used to regulate appetite, are no longer available for use.

More recently, CB1 cannabinoid receptor antagonists/inverse agonists have been suggested as potential appetite suppressants. See, e.g., Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," Psychopharmacol., 132, 104-106 (1997); Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," Life Sci., 63, PL113-PL117 (1998); Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmoset," Behav.

Pharmacol., **9**, 179-181 (1998); and Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," Psychopharmacology, **135**, 324-332 (1998). For a review of cannabinoid CB1 and CB2 receptor modulators, see Pertwee, R.G.,

5 "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," Exp. Opin. Invest. Drugs, **9**(7), 1553-1571 (2000).

Although investigations are on-going, there still exists a need for a more effective and safe therapeutic treatment for reducing or preventing

10 weight-gain.

In addition to obesity, there also exists an unmet need for treatment of alcohol abuse. Alcoholism affects approximately 10.9 million men and 4.4 million women in the United States. Approximately 100,000 deaths per year have been attributed to alcohol abuse or dependence. Health risks associated

15 with alcoholism include impaired motor control and decision making, cancer, liver disease, birth defects, heart disease, drug/drug interactions, pancreatitis and interpersonal problems. Studies have suggested that endogenous cannabinoid tone plays a critical role in the control of ethanol intake. The endogenous CB1 receptor antagonist SR-141716A has been shown to block



20 voluntary ethanol intake in rats and mice. See, Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," Psychopharmacol., **132**, 104-106 (1997). For a review, see Hungund, B.L and B.S. Basavarajappa, "Are Anandamide and Cannabinoid Receptors involved in Ethanol Tolerance? A

25 Review of the Evidence," Alcohol & Alcoholism, **35**(2) 126-133, 2000.

Current treatments for alcohol abuse or dependence generally suffer from non-compliance or potential hepatotoxicity; therefore, there is a high unmet need for more effective treatment of alcohol abuse/dependence.

SUMMARY

30 The present invention provides compounds of Formula (I) or (II).



wherein

- R^1 is an optionally substituted aryl or an optionally substituted heteroaryl (preferably, R^1 is a substituted phenyl, more preferably a phenyl substituted with one to three substituents independently selected from the group consisting of halo (preferably, chloro or fluoro), (C₁-C₄)alkoxy, (C₁-C₄)alkyl, halo-substituted (C₁-C₄)alkyl (preferably fluoro-substituted alkyl), and cyano, more preferably, R^1 is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl);

- R^2 is an optionally substituted aryl or an optionally substituted heteroaryl (preferably, R^2 is a substituted phenyl, more preferably a phenyl substituted with one to three substituents independently selected from the group consisting of halo (preferably, chloro or fluoro), (C₁-C₄)alkoxy, (C₁-C₄)alkyl, halo-substituted (C₁-C₄)alkyl (preferably fluoro-substituted alkyl), and cyano, more preferably, R^2 is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl);


- R^3 is hydrogen, (C₁-C₄)alkyl optionally substituted with one or more substituents, or (C₁-C₄)alkoxy; and

- R^4 is a chemical moiety selected from the group consisting of (C₁-C₉)alkyl, aryl, heteroaryl, aryl(C₁-C₅)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C₁-C₃)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 6-membered partially or fully saturated

heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

5 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt. Representative compounds have been shown to act as cannabinoid receptor ligands (in particular, CB1 receptor antagonists).

In another embodiment of the present invention, compounds of Formula (III) or (IV) are provided.



wherein

10 R^{1a} , R^{1b} , R^{2a} , and R^{2b} are each independently halo, (C_1 - C_4)alkoxy, (C_1 - C_4)alkyl, halo-substituted (C_1 - C_4)alkyl, or cyano;

m and n are each independently 0, 1 or 2 (preferably, m and n are each independently 0 or 1, more preferably, n is 0 and m is 1);

R^3 and R^4 are as defined above for the compounds of Formulae (I) and

15 (II);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

In preferred embodiments of compounds of Formula (I), (II), (III), and (IV),

20 R^3 is hydrogen, (C_1 - C_4)alkyl, halo-substituted (C_1 - C_4)alkyl, or (C_1 - C_4)alkoxy (preferably, R^2 is hydrogen, (C_1 - C_4)alkyl, or halo-substituted (C_1 - C_4)alkyl, more preferably, R^3 is hydrogen or methyl); and

R⁴ is a chemical moiety selected from (C₁-C₉)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring, or 3- to 6-membered partially or fully saturated heterocyclic ring, where the chemical moiety is optionally substituted with one or more substituents (more preferably, R⁴ is a (C₁-C₅)alkyl optionally substituted with phenyl, fluoro-substituted (C₁-C₅)alkyl, phenyl, cyclopentyl, cyclohexyl, pyranyl, furanyl, pyrrolidinyl, or piperidinyl); a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

Preferred compounds of Formula (I) or (III) include: 6-benzyl-3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one; 6-benzyl-3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one; and 3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2,2-trifluoro-ethyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one; or a pharmaceutically acceptable solvate or hydrate of the compound.

Preferred compounds of Formula (II) or (IV) include: 1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one; 2-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one; 2-(4-chloro-phenyl)-1-(2-chloro-phenyl)-5-cyclohexyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one; and 5-benzyl-2-(4-chloro-phenyl)-1-(2-chloro-phenyl)-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one; or a pharmaceutically acceptable solvate or hydrate of the compound.

Some of the compounds described herein contain at least one chiral center; consequently, those skilled in the art will appreciate that all stereoisomers (e.g., enantiomers and diastereoisomers) of the compounds illustrated and discussed herein are within the scope of the present invention. In addition, tautomeric forms of the compounds are also within the scope of the present invention.

Compounds of the present invention have been shown to be useful cannabinoid receptor ligands (in particular, CB1 receptor antagonists). Accordingly, another aspect of the present invention is a pharmaceutical composition that comprises (1) a compound of the present invention, and (2) a

pharmaceutically acceptable excipient, diluent, or carrier. Preferably, the composition comprises a therapeutically effective amount of a compound of the present invention. The composition may also contain at least one additional pharmaceutical agent (described herein). Preferred agents include

5 nicotine receptor partial agonists, opioid antagonists (e.g., naltrexone and naloxone), dopaminergic agents (e.g., apomorphine), attention deficit disorder (ADD including attention deficit hyperactivity disorder (ADHD)) agents (e.g., Ritalin™, Straterra™, Concerta™ and Adderall™), and anti-obesity agents (described herein below).

10 In yet another embodiment of the present invention, a method for treating a disease, condition or disorder modulated by a cannabinoid receptor (preferably, a CB1 receptor) antagonists in animals that includes the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of the present invention (or a pharmaceutical composition thereof).

Diseases, conditions, and/or disorders modulated by cannabinoid receptor antagonists include eating disorders (e.g., binge eating disorder, anorexia, and bulimia), weight loss or control (e.g., reduction in calorie or food intake, and/or appetite suppression), obesity, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors (e.g., conditioned place avoidance, such as suppression of cocaine- and morphine-induced conditioned place preference), substance abuse, addictive disorders, impulsivity, alcoholism (e.g., alcohol abuse, addiction and/or dependence including treatment for abstinence, craving reduction and relapse prevention of alcohol intake), tobacco abuse (e.g., smoking addiction, cessation and/or dependence including treatment for craving reduction and relapse prevention of tobacco smoking), dementia (including memory loss, Alzheimer's disease, dementia of aging, vascular dementia, mild cognitive impairment, age-related cognitive decline, and mild neurocognitive disorder), sexual dysfunction in males (e.g., erectile difficulty), seizure disorders, epilepsy, inflammation, gastrointestinal

disorders (e.g., dysfunction of gastrointestinal motility or intestinal propulsion), attention deficit disorder (ADD/ADHD), Parkinson's disease, and type II diabetes. In a preferred embodiment, the method is used in the treatment of weight loss, obesity, bulimia, ADD/ADHD, dementia, alcoholism, and/or

5 tobacco abuse.

Compounds of the present invention may be administered in combination with other pharmaceutical agents. Preferred pharmaceutical agents include nicotine receptor partial agonists, opioid antagonists (e.g., naltrexone (including naltrexone depot), antabuse, and nalmefene),

10 dopaminergic agents (e.g., apomorphine), ADD/ADHD agents (e.g., methylphenidate hydrochloride (e.g., Ritalin™ and Concerta™), atomoxetine (e.g., Straterra™), and amphetamines (e.g., Adderall™)) and anti-obesity agents, such as apo-B/MTP inhibitors, 11 β -hydroxy steroid dehydrogenase-1 (11 β -HSD type 1) inhibitors, peptide YY₃₋₃₆ or analogs thereof, MCR-4

15 agonists, CCK-A agonists, monoamine reuptake inhibitors, sympathomimetic agents, β_3 adrenergic receptor agonists, dopamine receptor agonists, melanocyte-stimulating hormone receptor analogs, 5-HT2c receptor agonists, melanin concentrating hormone receptor antagonists, leptin, leptin analogs, leptin receptor agonists, galanin receptor antagonists, lipase inhibitors,

20 bombesin receptor agonists, neuropeptide-Y receptor antagonists (e.g., NPY Y5 receptor antagonists such as those described hereinbelow), thyromimetic agents, dehydroepiandrosterone or analogs thereof, glucocorticoid receptor antagonists, orexin receptor antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors, human agouti-related protein

25 antagonists, ghrelin receptor antagonists, histamine 3 receptor antagonists or inverse agonists, and neuromedin U receptor agonists, and the like.

The combination therapy may be administered as (a) a single pharmaceutical composition which comprises a compound of the present invention, at least one additional pharmaceutical agent described herein and a

30 pharmaceutically acceptable excipient, diluent, or carrier; or (b) two separate pharmaceutical compositions comprising (i) a first composition comprising a

compound of the present invention and a pharmaceutically acceptable excipient, diluent, or carrier, and (ii) a second composition comprising at least one additional pharmaceutical agent described herein and a pharmaceutically acceptable excipient, diluent, or carrier. The pharmaceutical compositions
5 may be administered simultaneously or sequentially and in any order.

Definitions

As used herein, the term "alkyl" refers to a hydrocarbon radical of the general formula C_nH_{2n+1} . The alkane radical may be straight or branched. For example, the term "(C₁-C₆)alkyl" refers to a monovalent, straight, or branched 10 aliphatic group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, *t*-butyl, *n*-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, and the like). Similarly, the alkyl portion (i.e., alkyl moiety) of an alkoxy, acyl (e.g., alkanoyl), alkylamino, dialkylamino, and alkylthio group have the same 15 definition as above. When indicated as being "optionally substituted", the alkane radical or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally, one to three substituents except in the case of halogen substituents such as perchloro or perfluoroalkyls) independently selected from the group of substituents listed below in the definition for 20 "substituted." "Halo-substituted alkyl" refers to an alkyl group substituted with one or more halogen atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, and the like). When substituted, the alkane radicals or alkyl 25 moieties are preferably substituted with 1 to 3 fluoro substituents, or 1 or 2 substituents independently selected from (C₁-C₃)alkyl, (C₃-C₆)cycloalkyl, (C₂-C₃)alkenyl, aryl, heteroaryl, 3- to 6-membered heterocycle, chloro, cyano, hydroxy, (C₁-C₃)alkoxy, aryloxy, amino, (C₁-C₆)alkyl amino, di-(C₁-C₄)alkyl 30 amino, aminocarboxylate (i.e., (C₁-C₃)alkyl-O-C(O)-NH-), hydroxy(C₂-C₃)alkylamino, or keto (oxo), and more preferably, 1 to 3 fluoro groups, or 1 substituent selected from (C₁-C₃)alkyl, (C₃-C₆)cycloalkyl, (C₆)aryl, 6-membered-heteroaryl, 3- to 6-membered heterocycle, (C₁-C₃)alkoxy, (C₁-C₄)alkyl amino or di-(C₁-C₂)alkyl amino.

The terms "partially or fully saturated carbocyclic ring" (also referred to as "partially or fully saturated cycloalkyl") refers to nonaromatic rings that are either partially or fully hydrogenated and may exist as a single ring, bicyclic ring or a spiral ring. Unless specified otherwise, the carbocyclic ring is

5 generally a 3- to 8-membered ring (preferably, 3- to 6-membered ring). For example, partially or fully saturated carbocyclic rings (or cycloalkyl) include groups such as cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclpentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, norbornyl (bicyclo[2.2.1]heptyl), norbornenyl,

10 bicyclo[2.2.2]octyl, and the like. When designated as being "optionally substituted", the partially saturated or fully saturated cycloalkyl group may be unsubstituted or substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for "substituted." A substituted carbocyclic ring

15 also includes groups wherein the carbocyclic ring is fused to a phenyl ring (e.g., indanyl). The carbocyclic group may be attached to the chemical entity or moiety by any one of the carbon atoms within the carbocyclic ring system. When substituted, the carbocyclic group is preferably substituted with 1 or 2 substituents independently selected from (C₁-C₃)alkyl, (C₂-C₃)alkenyl, (C₁-C₆)alkylidenyl, aryl, heteroaryl, 3- to 6-membered heterocycle, chloro, fluoro, cyano, hydroxy, (C₁-C₃)alkoxy, aryloxy, amino, (C₁-C₆)alkyl amino, di-(C₁-C₄)alkyl amino, aminocarboxylate (i.e., (C₁-C₃)alkyl-O-C(O)-NH-), hydroxy(C₂-C₃)alkylamino, or keto (oxo), and more preferably 1 or 2 from substituents

20 independently selected from (C₁-C₂)alkyl, 3- to 6-membered heterocycle, fluoro, (C₁-C₃)alkoxy, (C₁-C₄)alkyl amino or di-(C₁-C₂)alkyl amino. Similarly, any cycloalkyl portion of a group (e.g., cycloalkylalkyl, cycloalkylamino, etc.)

25 has the same definition as above.

The term "partially saturated or fully saturated heterocyclic ring" (also referred to as "partially saturated or fully saturated heterocycle") refers to nonaromatic rings that are either partially or fully hydrogenated and may exist as a single ring, bicyclic ring or a spiral ring. Unless specified otherwise, the

heterocyclic ring is generally a 3- to 6-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen or nitrogen. Partially saturated or fully saturated heterocyclic rings include groups such as epoxy, aziridinyl, tetrahydrofuranyl, dihydrofuran, dihydropyridinyl, pyrrolidinyl, N-methylpyrrolidinyl, imidazolidinyl, imidazolinyl, piperidinyl, piperazinyl, pyrazolidinyl, 2H-pyranyl, 4H-pyranyl, 2H-chromenyl, oxazinyl, morpholino, thiomorpholino, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, and the like. When indicated as being "optionally substituted", the partially saturated or fully saturated heterocycle group may be unsubstituted or substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for "substituted." A substituted heterocyclic ring includes groups wherein the heterocyclic ring is fused to an aryl or heteroaryl ring (e.g., 2,3-dihydrobenzofuranyl, 2,3-dihydroindolyl, 2,3-dihydrobenzothiophenyl, 2,3-dihydrobenzothiazolyl, etc.). When substituted, the heterocycle group is preferably substituted with 1 or 2 substituents independently selected from (C_1 - C_3)alkyl, (C_3 - C_6)cycloalkyl, (C_2 - C_4)alkenyl, aryl, heteroaryl, 3- to 6-membered heterocycle, chloro, fluoro, cyano, hydroxy, (C_1 - C_3)alkoxy, aryloxy, amino, (C_1 - C_6)alkyl amino, di-(C_1 - C_3)alkyl amino, aminocarboxylate (i.e., (C_1 - C_3)alkyl-O-C(O)-NH-), or keto (oxo), and more preferably with 1 or 2 substituents independently selected from (C_1 - C_3)alkyl, (C_3 - C_6)cycloalkyl, (C_6)aryl, 6-membered-heteroaryl, 3- to 6-membered heterocycle, or fluoro. The heterocyclic group may be attached to the chemical entity or moiety by any one of the ring atoms within the heterocyclic ring system. Similarly, any heterocycle portion of a group (e.g., heterocycle-substituted alkyl, heterocycle carbonyl, etc.) has the same definition as above.

The term "aryl" or "aromatic carbocyclic ring" refers to aromatic moieties having a single (e.g., phenyl) or a fused ring system (e.g., naphthalene, anthracene, phenanthrene, etc.). A typical aryl group is a 6- to 10-membered aromatic carbocyclic ring(s). When indicated as being

"optionally substituted", the aryl groups may be unsubstituted or substituted with one or more substituents (preferably no more than three substituents) independently selected from the group of substituents listed below in the definition for "substituted." Substituted aryl groups include a chain of aromatic moieties (e.g., biphenyl, terphenyl, phenylnaphthalyl, etc.). When substituted, the aromatic moieties are preferably substituted with 1 or 2 substituents independently selected from (C₁-C₄)alkyl, (C₂-C₃)alkenyl, aryl, heteroaryl, 3- to 6-membered heterocycle, bromo, chloro, fluoro, iodo, cyano, hydroxy, (C₁-C₄)alkoxy, aryloxy, amino, (C₁-C₆)alkyl amino, di-(C₁-C₃)alkyl amino, or aminocarboxylate (i.e., (C₁-C₃)alkyl-O-C(O)-NH-), and more preferably, 1 or 2 substituents independently selected from (C₁-C₄)alkyl, chloro, fluoro, cyano, hydroxy, or (C₁-C₄)alkoxy. The aryl group may be attached to the chemical entity or moiety by any one of the carbon atoms within the aromatic ring system. Similarly, the aryl portion (i.e., aromatic moiety) of an aroyl or aryloxy (i.e., (aryl)-C(O)-O-) has the same definition as above.

The term "heteroaryl" or "heteroaromatic ring" refers to aromatic moieties containing at least one heteroatom (e.g., oxygen, sulfur, nitrogen or combinations thereof) within a 5- to 10-membered aromatic ring system (e.g., 20 pyrrolyl, pyridyl, pyrazolyl, indolyl, indazolyl, thienyl, furanyl, benzofuranyl, oxazolyl, imidazolyl, tetrazolyl, triazinyl, pyrimidyl, pyrazinyl, thiazolyl, purinyl, benzimidazolyl, quinolinyl, isoquinolinyl, benzothiophenyl, benzoxazolyl, etc.). The heteroaromatic moiety may consist of a single or fused ring system. A typical single heteroaryl ring is a 5- to 6-membered ring containing one to 25 three heteroatoms independently selected from oxygen, sulfur and nitrogen and a typical fused heteroaryl ring system is a 9- to 10-membered ring system containing one to four heteroatoms independently selected from oxygen, sulfur and nitrogen. When indicated as being "optionally substituted", the heteroaryl groups may be unsubstituted or substituted with one or more substituents (preferably no more than three substituents) independently selected from the group of substituents listed below in the definition for 30

"substituted." When substituted, the heteroaromatic moieties are preferably substituted with 1 or 2 substituents independently selected from (C₁-C₄)alkyl, (C₂-C₃)alkenyl, aryl, heteroaryl, 3- to 6-membered heterocycle, bromo, chloro, fluoro, iodo, cyano, hydroxy, (C₁-C₄)alkoxy, aryloxy, amino, (C₁-C₆)alkyl amino, di-(C₁-C₃)alkyl amino, or aminocarboxylate (i.e., (C₁-C₃)alkyl-O-C(O)-NH-), and more preferably, 1 or 2 substituents independently selected from (C₁-C₄)alkyl, chloro, fluoro, cyano, hydroxy, (C₁-C₄)alkoxy, (C₁-C₄)alkyl amino or di-(C₁-C₂)alkyl amino. The heteroaryl group may be attached to the chemical entity or moiety by any one of the atoms within the aromatic ring system (e.g., imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrid-5-yl, or pyrid-6-yl). Similarly, the heteroaryl portion (i.e., heteroaromatic moiety) of a heteroaroyl or heteroaroyloxy (i.e., (heteroaryl)-C(O)-O-) has the same definition as above.

The term "acyl" refers to alkyl, partially saturated or fully saturated cycloalkyl, partially saturated or fully saturated heterocycle, aryl, and heteroaryl substituted carbonyl groups. For example, acyl includes groups such as (C₁-C₆)alkanoyl (e.g., formyl, acetyl, propionyl, butyryl, valeryl, caproyl, *t*-butylacetyl, etc.), (C₃-C₆)cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, etc.), heterocyclic carbonyl (e.g., pyrrolidinylcarbonyl, pyrrolid-2-one-5-carbonyl, piperidinylcarbonyl, piperazinylcarbonyl, tetrahydrofuranylcarbonyl, etc.), aroyl (e.g., benzoyl) and heteroaroyl (e.g., thiophenyl-2-carbonyl, thiophenyl-3-carbonyl, furanyl-2-carbonyl, furanyl-3-carbonyl, 1H-pyrrolyl-2-carbonyl, 1H-pyrrolyl-3-carbonyl, benzo[b]thiophenyl-2-carbonyl, etc.). In addition, the alkyl, cycloalkyl, heterocycle, aryl and heteroaryl portion of the acyl group may be any one of the groups described in the respective definitions above. When indicated as being "optionally substituted", the acyl group may be unsubstituted or optionally substituted with one or more substituents (typically, one to three substituents) independently selected from the group of substituents listed below in the definition for "substituted" or the alkyl, cycloalkyl, heterocycle, aryl and

heteroaryl portion of the acyl group may be substituted as described above in the preferred and more preferred list of substituents, respectively.

The term "substituted" specifically envisions and allows for one or more substitutions that are common in the art. However, it is generally understood

- 5 by those skilled in the art that the substituents should be selected so as to not adversely affect the pharmacological characteristics of the compound or adversely interfere with the use of the medicament. Suitable substituents for any of the groups defined above include (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, (C₂-C₆)alkenyl, (C₁-C₆)alkylenyl, aryl, heteroaryl, 3- to 6-membered heterocycle,
- 10 halo (e.g., chloro, bromo, iodo and fluoro), cyano, hydroxy, (C₁-C₆)alkoxy, aryloxy, sulfhydryl (mercapto), (C₁-C₆)alkylthio, arylthio, amino, mono- or di-(C₁-C₆)alkyl amino, quaternary ammonium salts, amino(C₁-C₆)alkoxy, aminocarboxylate (i.e., (C₁-C₆)alkyl-O-C(O)-NH-), hydroxy(C₂-C₆)alkylamino, amino(C₁-C₆)alkylthio, cyanoamino, nitro, (C₁-C₆)carbamyl, keto (oxo), acyl,
- 15 (C₁-C₆)alkyl-CO₂-, glycolyl, glycyl, hydrazino, guanyl, sulfamyl, sulfonyl, sulfinyl, thio(C₁-C₆)alkyl-C(O)-, thio(C₁-C₆)alkyl-CO₂-, and combinations thereof. In the case of substituted combinations, such as "substituted aryl(C₁-C₆)alkyl", either the aryl or the alkyl group may be substituted, or both the aryl and the alkyl groups may be substituted with one or more substituents
- 20 (typically, one to three substituents except in the case of perhalo substitutions). An aryl or heteroaryl substituted carbocyclic or heterocyclic group may be a fused ring (e.g., indanyl, dihydrobenzofuranyl, dihydroindolyl, etc.).

The term "halo" refers to a chloro, bromo, fluoro or iodo group.

- 25 The term "solvate" refers to a molecular complex of a compound represented by Formula (I) or (II) (including prodrugs and pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water.
- 30

The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.

5 The term "protecting group" or "Pg" refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups
10 include acetyl, trifluoroacetyl, *t*-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a "hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy
15 group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include alkyl, $-\text{CH}_2\text{CH}_2\text{SO}_2\text{Ph}$, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(*p*-toluenesulfonyl)ethyl, 2-(*p*-nitrophenylsulfonyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see T. W.
20 Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

25 The phrase "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.

30 The term "animal" refers to humans (male or female), companion animals (e.g., dogs, cats and horses), food-source animals, zoo animals, marine animals, birds and other similar animal species. "Edible animals"

refers to food-source animals such as cows, pigs, sheep and poultry. A preferred animal is a human.

The terms "treating", "treat", or "treatment" embrace both preventative, i.e., prophylactic, and palliative treatment.

5 The terms "modulated by a cannabinoid receptor" or "modulation of a cannabinoid receptor" refers to the activation or deactivation of a cannabinoid receptor. For example, a ligand may act as an agonist, partial agonist, inverse agonist, antagonist, or partial antagonist.

10 The term "antagonist" includes both full antagonists and partial antagonists, as well as inverse agonists.

The term "CB-1 receptor" refers to the G-protein coupled type 1 cannabinoid receptor.

15 The term "compounds of the present invention" (unless specifically identified otherwise) refer to compounds of Formulae (I), (II), (III) and (IV), prodrugs thereof, pharmaceutically acceptable salts of the compounds, and/or prodrugs, and hydrates or solvates of the compounds, salts, and/or prodrugs, as well as, all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds.

20 DETAILED DESCRIPTION

Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Aldrich 25 Chemicals (Milwaukee, WI) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also 30 available via the Beilstein online database)).

For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds.

5 Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below


10 can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.

In the preparation of compounds of the present invention, protection of remote functionality (e.g., primary or secondary amine) of intermediates may be necessary. The need for such protection will vary depending on the nature

15 of the remote functionality and the conditions of the preparation methods. Suitable amino-protecting groups (NH-Pg) include acetyl, trifluoroacetyl, *t*-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). The need for such protection is readily determined by one skilled in the art. For a general description of

20 protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.

Scheme I below illustrates an approach for preparing the 2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one derivatives (i.e., compounds of Formulae (I) and (III)).


**Scheme I**

An appropriately substituted hydrazine hydrochloride salt can be first reacted with diethylacetylene dicarboxylate in a polar solvent (e.g., ethanol) at refluxing conditions to produce the pyrazolone intermediate (1a). Suitable hydrazine compounds are available commercially or can be readily prepared using procedures well-known to those skilled in the art. The pyrazolone

derivatives may be synthesized using methods analogous to those described in Acta Chemica Hungarica, 122(3-4), 211-15 (1986). The pyrazolone (1a) can then be treated with phosphorus oxychloride in a polar solvent (e.g., dimethylformamide (DMF)) to produce the chloroaldehyde (1b). The chloro 5 aldehyde derivatives can be synthesized using procedures analogous to those described in Journal of Heterocyclic Chemistry, 27(2), 2434-5 (1990). The chloroaldehyde (1b) can be reacted with alkyl or aryl organometallic reagent, such as dialkylzinc, alkylmagnesium chloride or bromide, and arylmagnesium chloride or bromide, to provide an intermediate alcohol 10 derivative which can be oxidized to the ketone (1c) using oxidizing reagents, such as pyridinium chlorochromate (PCC), CrO₃, Swern oxidation conditions and others well known to chemists skilled in the art. The conditions for the addition of organometallic reagents are as those described in Heterocycles, 53(2), 381-386 (2000). The oxidation conditions are as described in 15 Heterocycles, 29(10), 381-386 (1989). The hydrazone (1d) can then be formed from chloroaldehyde intermediate (1b) or ketone (1c) by reacting the chloroaldehyde (1b) or ketone (1c) with a protected hydrazine using procedures analogous to those described in Pharmazie, 54(2), 106-111 (1999). Preferred protecting groups include t-butylcarbamoyl, benzyl, 20 benzyloxy carbamoyl, acetyl, and the like. Use of t-butyl carbamoyl is preferred because of ease of deprotection during cyclization. The hydrazone (1d) can then be heated to 60°-100°C in the presence of acids (e.g., acetic acid, HCl, or pTsOH) in solvents such as DMF, dioxane, or toluene to provide the pyridazinone (1e). The pyridazinone (1e) can then be reacted with a 25 suitable aryl boronic acid, according to the procedures described in Tetrahedron, 56, 5499 (2000), using tetrakis(triphenylphosphine) as a catalyst to provide the desired aryl substituted pyridazinone (1f). Other Suzuki reaction conditions can also be used to prepare the aryl pyridazinone (1f) (see, e.g., Chem. Rev. 2457 (1995) and references cited therein). 30 The pyridazinone (1f) can be treated with alkyl halides in the presence of base in a solvent such as DMF, THF, DMSO, NMP, etc to provide

pyridazinone (1g). The alkyl halides are generally commercially available. Other leaving groups such as the sulfonate groups (e.g., triflate and mesylate) can also be used instead of alkyl halides. The generally preferred base is sodium hydride but other bases can be used, such as potassium carbonate, sodium hydroxide, etc. The reactions can also be performed according to procedures described in Tetrahedron (2002), 58, 9933 and references cited therein.

An alternative procedure for preparing the 2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one derivatives (i.e., compounds of Formulas (I) and (III)) is shown below in Scheme II.



10


Scheme II

The aldehyde or ketone intermediate (2a), prepared as described in Scheme I, can be converted to the acid (2b) by reacting with a suitable base (e.g., lithium hydroxide, sodium hydroxide or potassium hydroxide) in an alcoholic solvent (e.g., ethanol). The acid (2b) can be reacted with a chlorinating agent (e.g., oxalyl chloride or thionyl chloride) to generate an

15

intermediate acyl chloride derivative which can be treated *in situ* with an appropriately substituted alkyl hydrazine derivative to provide the pyridazinone intermediate (2c). Cross-coupling of intermediate (2c) with an arylboronic acid in the presence of a palladium catalyst (e.g., 5 tetraakis(triphenylphosphine)palladium) as described previously can yield compounds of Formula (I) or (III).

Scheme III below illustrates a method for preparing compounds of Formulae (II) or (IV), where R³ is hydrogen (i.e., compounds of Formula II-A).



Scheme III

Intermediate (3a) can be prepared by treating the appropriate amine having the desired R² group with trimethylaluminum under inert atmospheric conditions followed by condensation with the appropriate cyanide having the desired R¹ group. Suitable amines include substituted phenyl amines (e.g., 4-chlorophenyl amine, 4-fluorophenyl amine, 4-bromophenyl amine, 4-iodophenyl amine, 4-cyanophenyl amine, and the like) pyridin-2-yl amine, pyridin-3-yl amine, pyridin-4-yl amine, substituted pyridinyl amines (e.g., 2-dimethylaminopyridin-5-yl amine, 2-methoxypyridin-5-yl amine, 5-chloropyridin-2-yl amine, 5-methylpyridin-2-yl, 5-methoxypyridin-2-yl amine, 3-chloropyridin-4-yl amine, 2-N-morpholinylpyridin-5-yl, and the like), and other commercially available or easily synthesized substituted or unsubstituted aryl and heteroaryl amines. Suitable cyano compounds include substituted benzonitriles (e.g., 2-chlorobenzonitrile, 2-fluorobenzonitrile, 2-methoxybenzonitrile, 2-methylbenzonitrile, 2,4-dichlorobenzonitrile, 2,4-difluorobenzonitrile, 2-chloro-4-fluorobenzonitrile, 2-chloro-4-methylbenzonitrile, 2,4-dimethoxybenzonitrile, 2-methyl-4-chlorobenzonitrile, and the like), cyano-substituted pyridines (e.g., 4-cyano-3-chloropyridine) and other commercially available or easily synthesized substituted or unsubstituted aryl or heteroaryl nitriles.

Intermediate (3a) can then be condensed with a 3-bromo-2-oxo-propionic acid ester to produce the cyclized 4-hydroxy-4,5-dihydro-1H-imidazole ester (3b) using procedures analogous to those described by Khanna, I.K., et al., in J. Med. Chem., 40, 1634 (1997). For example, the amidine intermediate (3a) is refluxed in a polar solvent (e.g., isopropanol) in the presence of a mild base (e.g., sodium bicarbonate). Generally, the reaction (i.e., cyclization followed by dehydration) proceeds directly to the desired imidazole ester intermediate (3c). In some instances, it may be necessary to dehydrate the carbinol condensation product (3b) with an acid catalyst (e.g., p-toluenesulfonic acid in refluxing toluene) to provide the desired imidazole ester (3c). Alternatively, intermediate (3b) can be treated

with methanesulfonyl chloride in the presence of a base (e.g., triethylamine) to provide (3c).

Intermediate (3d, where L¹ is a halogen) can be synthesized from imidazole ester (3c) using a halogenating agent such as bromine, N-bromosuccinimide, iodine, or N-iodosuccinamide in a suitable protic solvent such as glacial acetic acid or trifluoroacetic acid or an aprotic solvent such as acetonitrile, ether or THF, at reaction temperatures ranging from 35° – 100°C.

In a preferred example, intermediate I-3c is treated with bromine in glacial acetic acid at room temperature. Transmetalation of (3d) using an alkyl lithium base, preferentially n-BuLi or *tert*-butyl lithium, or an alkyl Grignard reagent such MeMgBr or EtMgBr, in a polar, aprotic solvent (e.g., diethyl ether, dioxane or THF) at reaction temperatures ranging from –100° to –78°C, followed by treatment with a formyl equivalent (e.g., DMF, formylpiperidine, or ethyl formate) provides the aldehyde derivative (3e). Alternatively,


intermediate (3e) may be prepared directly from (3c) by treatment with Vilsmeier reagent (prepared from an equivalent of POCl₃ or POBr₃ and an equivalent of DMF) in a solvent such as DMF or CH₂Cl₂, followed by hydrolysis.

The aldehyde intermediate (3e) can be reacted with aqueous hydrazine in a polar solvent (e.g., ethanol) at refluxing temperatures to give intermediate (3f) which can be cyclized to (3g) in a non-polar solvent (e.g., benzene, toluene) under refluxing conditions in the presence of an acid catalyst (e.g., p-TsOH, HOAc). Treatment of (3g) with R⁴-L where L is a suitable leaving group (e.g., Cl, Br, OTf) in a polar, aprotic solvent (e.g., DMF, N-methylpyrrolidinone) in the presence of a base (e.g., Cs₂CO₃, K₂CO₃, KH) can provide compounds of Formula (II-A).

The aldehyde intermediate (3a) can alternatively be reacted with an appropriately substituted hydrazine derivative (R⁴NHNH₂) in an alcoholic solvent such as ethanol in the presence of an acid catalyst (e.g., HOAc) to give compounds of Formula (II-A). In certain instances, it may be necessary

to replace the alcoholic solvent with a higher boiling non-polar solvent such as toluene in order to facilitate the cyclocondensation reaction.

Scheme IV illustrates an alternative method for synthesizing aldehyde intermediate (3e).




Scheme IV

Intermediate (3a) can be condensed with a 3-bromo-4-hydroxy-2-oxo-butyric acid alkyl ester derivative containing a suitable protecting group on the 4-hydroxyl substituent [(4a), see Tetrahedron, **51**, 4867-90 (1995)] to give the cyclized intermediate (4b) which can be dehydrated as previously described to yield the imidazoyl intermediate (4c). The protecting group (Pg) on the 5-hydroxymethyl group in intermediate (4c) can be subsequently removed by standard procedures well known to those skilled in the art. Intermediate (4d) can then be transformed into (3e) using oxidation procedures analogous to those described in Tett. Lett., **35**, 9391-4 (1994) or J. Het. Chem., **39**, 841-844 (2002). For example, the 5-hydroxymethylimidazoyl derivative (4d) can be treated with oxalyl chloride, DMSO and a tertiary amine base such as

triethylamine or diisopropylethylamine in a halogenated solvent such as CH₂Cl₂ or CHCl₃. Alternatively, the intermediate (4d) can be oxidized using MnO₂ in a polar or non-polar solvent such as MeOH, acetone, dioxane, ether, CH₂Cl₂, or CHCl₃.

- 5 Compounds of Formula (II-B) or (IV-B) where R³ is an alkyl or aryl group can be prepared by the route shown in Scheme V.



Scheme V

10 Intermediate (3d) can be reacted with an alkyl lithium base, preferably, n-BuLi or *tert*-butyl lithium, or an alkyl Grignard reagent such as MeMgBr or EtMgBr, in a polar, aprotic solvent such as diethyl ether, dioxane or THF, at reaction temperatures ranging from -100° to -78°C, and then treated with an acylating agent (e.g., R³CO₂Et, R³CONMe₂) to provide intermediate (5a).

15 Reaction of (5a) with an appropriately substituted hydrazine derivative in a polar solvent (e.g., ethanol) can provide compounds of Formula (II-B), including compounds of Formula (IV-B), where R¹ and R² are substituted phenyls.

Conventional methods and/or techniques of separation and purification known to one of ordinary skill in the art can be used to isolate the compounds of the present invention, as well as the various intermediates related thereto. Such techniques will be well-known to one of ordinary skill in the art and may include, for example, all types of chromatography (high pressure liquid chromatography (HPLC), column chromatography using common adsorbents such as silica gel, and thin-layer chromatography), recrystallization, and differential (i.e., liquid-liquid) extraction techniques.

The compounds of the present invention may be isolated and used *per se* or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate. The term "salts" refers to inorganic and organic salts of a compound of the present invention. These salts can be prepared *in situ* during the final isolation and purification of a compound, or by separately reacting the compound, or prodrug with a suitable organic or inorganic acid or base and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, hydroiodide, sulfate, bisulfate, nitrate, acetate, trifluoroacetate, oxalate, besylate, palmitate, pamoate, malonate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, hexafluorophosphate, benzene sulfonate, tosylate, formate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate salts, and the like. The salts may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. See, e.g., Berge, et al., *J. Pharm. Sci.*, 66, 1-19 (1977).

The term "prodrug" means a compound that is transformed *in vivo* to yield a compound of Formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C_1-C_8)alkyl, (C_2-C_{12})alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to

9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-

- 5 (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C₁-C₂)alkyl, N,N-di(C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl and piperidino-, pyrrolidino- or morpholino(C₂-C₃)alkyl.

- 10 Similarly, if a compound of the present invention contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C₁-C₆)alkanoyloxymethyl, 1-((C₁-C₆)alkanoyloxy)ethyl, 1-methyl-1-((C₁-C₆)alkanoyloxy)ethyl, (C₁-C₆)alkoxycarbonyloxymethyl, N-(C₁-C₆)alkoxycarbonylaminomethyl, succinoyl, (C₁-C₆)alkanoyl, α-amino(C₁-C₄)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is selected from the naturally occurring L-amino acids, P(O)(OH)₂, P(O)(O(C₁-C₆)alkyl)₂ or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

- 15 If a compound of the present invention incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (C₁-C₁₀)alkyl, (C₃-C₇)cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl-natural α-aminoacyl, -C(OH)C(O)OY' wherein Y' is H, (C₁-C₆)alkyl or benzyl, -C(OY₀)Y₁ wherein Y₀ is (C₁-C₄) alkyl and Y₁ is (C₁-C₆)alkyl, carboxy(C₁-C₆)alkyl, amino(C₁-C₄)alkyl or mono-N- or di-N,N-(C₁-C₆)alkylaminoalkyl, -C(Y₂)Y₃ wherein Y₂ is H or methyl and Y₃ is mono-N- or 20 di-N,N-(C₁-C₆)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yl.

The compounds of the present invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the present invention as well as mixtures thereof, including racemic mixtures, form part of 5 the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the present invention incorporates a double bond or a fused ring, both the *cis*- and *trans*-forms, as well as mixtures, are embraced within the scope of the invention.

Diastereomeric mixtures can be separated into their individual 10 diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral 15 alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers. Also, some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by 20 use of a chiral HPLC column.

The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

It is also possible that the intermediates and compounds of the present 25 invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies which are interconvertible *via* a low energy barrier. For example, proton tautomers (also 30 known as prototropic tautomers) include interconversions *via* migration of a proton, such as keto-enol and imine-enamine isomerizations. A specific

example of a proton tautomer is the imidazole moiety where the proton may migrate between the two ring nitrogens. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

The present invention also embraces isotopically-labeled compounds 5 of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, 10 oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{123}I and ^{125}I , respectively.

Certain isotopically-labeled compounds of the present invention (e.g., 15 those labeled with ^3H and ^{14}C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ^3H) and carbon-14 (i.e., ^{14}C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., 20 increased *in vivo* half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as ^{15}O , ^{13}N , ^{11}C , and ^{18}F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by following procedures 25 analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

Another aspect of the present invention is a method of treating 30 diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in an animal that includes administering to an animal in need of such treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition comprising an effective

amount of a compound of the present invention and a pharmaceutically acceptable excipient, diluent, or carrier. The method is particularly useful for treating diseases, conditions and/or disorders modulated by cannabinoid receptor (in particular, CB1 receptor) antagonists.

- 5 Preliminary investigations have indicated that the following diseases, conditions, and/or disorders are modulated by cannabinoid receptor antagonists: eating disorders (e.g., binge eating disorder, anorexia, and bulimia), weight loss or control (e.g., reduction in calorie or food intake, and/or appetite suppression), obesity, depression, atypical depression, bipolar
- 10 disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors (e.g., conditioned place avoidance, such as suppression of cocaine- and morphine-induced conditioned place preference), substance abuse, addictive disorders, impulsivity, alcoholism (e.g., alcohol abuse, addiction and/or dependence including treatment for abstinence, craving reduction and relapse prevention of alcohol intake), tobacco abuse
- 15 (e.g., smoking addiction, cessation and/or dependence including treatment for craving reduction and relapse prevention of tobacco smoking), dementia (including memory loss, Alzheimer's disease, dementia of aging, vascular dementia, mild cognitive impairment, age-related cognitive decline, and mild neurocognitive disorder), sexual dysfunction in males (e.g., erectile difficulty), seizure disorders, epilepsy, inflammation, gastrointestinal disorders (e.g., dysfunction of gastrointestinal motility or intestinal propulsion), attention deficit disorder (ADD including attention deficit hyperactivity disorder (ADHD)), Parkinson's disease, and type II diabetes.
- 20 Accordingly, the compounds of the present invention described herein are useful in treating diseases, conditions, or disorders that are modulated by cannabinoid receptor antagonists. Consequently, the compounds of the present invention (including the compositions and processes used therein) may be used in the manufacture of a medicament for the therapeutic
- 25 applications described herein.

Other diseases, conditions and/or disorders for which cannabinoid receptor antagonists may be effective include: premenstrual syndrome or late luteal phase syndrome, migraines, panic disorder, anxiety, post-traumatic syndrome, social phobia, cognitive impairment in non-demented individuals,

5 non-amnestic mild cognitive impairment, post operative cognitive decline, disorders associated with impulsive behaviours (such as, disruptive behaviour disorders (e.g., anxiety/depression, executive function improvement, tic disorders, conduct disorder and/or oppositional defiant disorder), adult personality disorders (e.g., borderline personality disorder and antisocial

10 personality disorder), diseases associated with impulsive behaviours (e.g., substance abuse, paraphilias and self-mutilation), and impulse control disorders (e.g., intermittent explosive disorder, kleptomania, pyromania, pathological gambling, and trichotillomania)), obsessive compulsive disorder, chronic fatigue syndrome, sexual dysfunction in males (e.g., premature

15 ejaculation), sexual dysfunction in females, disorders of sleep (e.g., sleep apnea), autism, mutism, neurodegenerative movement disorders, spinal cord injury, damage of the central nervous system (e.g., trauma), stroke, neurodegenerative diseases or toxic or infective CNS diseases (e.g., encephalitis or meningitis), cardiovascular disorders (e.g., thrombosis), and

20 diabetes.

The compounds of the present invention can be administered to a patient at dosage levels in the range of from about 0.7 mg to about 7,000 mg per day. For a normal adult human having a body weight of about 70 kg, a dosage in the range of from about 0.01 mg to about 100 mg per kilogram body weight is typically sufficient. However, some variability in the general dosage range may be required depending upon the age and weight of the subject being treated, the intended route of administration, the particular compound being administered and the like. The determination of dosage ranges and optimal dosages for a particular patient is well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure. It is also noted that the compounds of the present invention can be used in sustained

release, controlled release, and delayed release formulations, which forms are also well known to one of ordinary skill in the art.

The compounds of this invention may also be used in conjunction with other pharmaceutical agents for the treatment of the diseases, conditions

- 5 and/or disorders described herein. Therefore, methods of treatment that include administering compounds of the present invention in combination with other pharmaceutical agents are also provided. Suitable pharmaceutical agents that may be used in combination with the compounds of the present invention include anti-obesity agents such as apolipoprotein-B
- 10 secretion/microsomal triglyceride transfer protein (apo-B/MTP) inhibitors, 11 β -hydroxy steroid dehydrogenase-1 (11 β -HSD type 1) inhibitors, peptide YY₃₋₃₆ or analogs thereof, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors (such as sibutramine), sympathomimetic agents, β_3 adrenergic receptor agonists, dopamine agonists (such as bromocriptine), melanocyte-stimulating hormone receptor analogs, 5HT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin receptor agonists, galanin antagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e. orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Y antagonists (e.g., NPY Y5 receptor
- 15 antagonists, such as the spiro compounds described in US Patent Nos. 6,566,367; 6,649,624; 6,638,942; 6,605,720; 6,495,559; 6,462,053; 6,388,077; 6,335,345; and 6,326,375; US Publication Nos. 2002/0151456 and 2003/036652; and PCT Publication Nos. WO 03/010175, WO 03/082190 and WO 02/048152), thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid receptor agonists or antagonists, orexin receptor antagonists, glucagon-like peptide-1 receptor agonists, ciliary neurotrophic factors (such as Axokine™ available from Regeneron Pharmaceuticals, Inc., Tarrytown, NY and Procter & Gamble Company, Cincinnati, OH), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3
- 20 receptor antagonists or inverse agonists, neuromedin U receptor agonists and the like. Other anti-obesity agents, including the preferred agents set forth

hereinbelow, are well known, or will be readily apparent in light of the instant disclosure, to one of ordinary skill in the art.

Especially preferred are anti-obesity agents selected from the group consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, 5 pseudoephedrine, PYY₃₋₃₆ or an analog thereof, and 2-oxo-N-(5-phenylpyrazinyl)spiro-[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide. Preferably, compounds of the present invention and combination therapies are administered in conjunction with exercise and a sensible diet.

Representative anti-obesity agents for use in the combinations, 10 pharmaceutical compositions, and methods of the invention can be prepared using methods known to one of ordinary skill in the art, for example, sibutramine can be prepared as described in U.S. Pat. No. 4,929,629; bromocriptine can be prepared as described in U.S. Pat. Nos. 3,752,814 and 3,752,888; orlistat can be prepared as described in U.S. Pat. Nos. 5,274,143; 15 5,420,305; 5,540,917; and 5,643,874; PYY₃₋₃₆ (including analogs thereof) can be prepared as described in US Publication No. 2002/0141985 and WO 03/027637; and the NPY Y5 receptor antagonist 2-oxo-N-(5-phenylpyrazinyl)spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide can be prepared as described in US Publication No. 2002/0151456. Other useful 20 NPY Y5 receptor antagonists include those described in PCT Publication No. 03/082190, such as 3-oxo-N-(5-phenyl-2-pyrazinyl)-spiro[isobenzofuran-1(3H), 4'-piperidine]-1'-carboxamide; 3-oxo-N-(7-trifluoromethylpyrido[3,2-b]pyridin-2-yl)-spiro-[isobenzofuran-1(3H), 4'-piperidine]-1'-carboxamide; N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro-[isobenzofuran-1(3H), [4'-piperidine]-1'-carboxamide; *trans*-3'-oxo-N-(5-phenyl-2-pyrimidinyl)]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; *trans*-3'-oxo-N-[1-(3-quinolyl)-4-imidazolyl]spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; *trans*-3'-oxo-N-(5-phenyl-2-pyrazinyl)spiro[4-azaisobenzofuran-1(3H), 1'-cyclohexane]-4'-carboxamide; *trans*-N-[5-(3-fluorophenyl)-2-pyrimidinyl]-3-oxospiro[5-azaisobenzofuran-1(3H), 1'-cyclohexane]-4'-carboxamide; *trans*-N-[5-(2-fluorophenyl)-2-pyrimidinyl]-3-

oxospiro[5-azaisobenzofuran-1(3H), 1'-cyclohexane]-4'-carboxamide; *trans*-N-[1-(3,5-difluorophenyl)-4-imidazoly]-3-oxospiro[7-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; *trans*-3-oxo-N-(1-phenyl-4-pyrazolyl)spiro[4-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; 5 *trans*-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; *trans*-3-oxo-N-(1-phenyl-3-pyrazolyl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; *trans*-3-oxo-N-(2-phenyl-1,2,3-triazol-4-yl)spiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide; and pharmaceutically acceptable salts and 10 esters thereof. All of the above recited U.S. patents and publications are incorporated herein by reference.

Other suitable pharmaceutical agents that may be administered in combination with the compounds of the present invention include agents designed to treat tobacco abuse (e.g., nicotine receptor partial agonists, 15 bupropion hydrochloride (also known under the trade name Zyban™) and nicotine replacement therapies), agents to treat erectile dysfunction (e.g., dopaminergic agents, such as apomorphine), ADD/ADHD agents (e.g., Ritalin™, Straterra™, Concerta™ and Adderall™), and agents to treat alcoholism, such as opioid antagonists (e.g., naltrexone (also known under 20 the tradename ReVia™) and naloxone), disulfiram (also known under the tradename Antabuse™), and acamprosate (also known under the trade name Campral™)). In addition, agents for reducing alcohol withdrawal symptoms may also be co-administered, such as benzodiazepines, beta-blockers, clonidine, carbamazepine, pregabalin, and gabapentin (Neurontin™). 25 Treatment for alcoholism is preferably administered in combination with behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including Alcohol Anonymous (AA).

Other pharmaceutical agents that may be useful include 30 antihypertensive agents; anti-inflammatory agents (e.g., COX-2 inhibitors); antidepressants (e.g., fluoxetine hydrochloride (Prozac™)); cognitive

improvement agents (e.g., donepezil hydrochloride (Aircept™) and other acetylcholinesterase inhibitors); neuroprotective agents (e.g., memantine); antipsychotic medications (e.g., ziprasidone (Geodon™), risperidone (Risperdal™), and olanzapine (Zyprexa™)); insulin and insulin analogs (e.g., 5 LysPro insulin); GLP-1 (7-37) (insulinotropin) and GLP-1 (7-36)-NH₂; sulfonylureas and analogs thereof: chlorpropamide, glibenclamide, tolbutamide, tolazamide, acetohexamide, Glypizide®, glimepiride, repaglinide, meglitinide; biguanides: metformin, phenformin, buformin; α₂-antagonists and imidazolines: midaglizole, isaglidole, deriglidole, idazoxan, efaxorphan, 10 fluparoxan; other insulin secretagogues: linagliptide, A-4166; glitazones: ciglitazone, Actos® (pioglitazone), englitazone, troglitazone, darglitazone, Avandia® (BRL49653); fatty acid oxidation inhibitors: clomoxir, etomoxir; α-glucosidase inhibitors: acarbose, miglitol, emiglitate, voglibose, MDL-25,637, camiglibose, MDL-73,945; β-agonists: BRL 35135, BRL 37344, RO 16-8714, 15 ICI D7114, CL 316,243; phosphodiesterase inhibitors: L-386,398; lipid-lowering agents: benfluorex; fenfluramine; vanadate and vanadium complexes (e.g., Naglivan®) and peroxovanadium complexes; amylin antagonists; glucagon antagonists; gluconeogenesis inhibitors; somatostatin analogs; antilipolytic agents: nicotinic acid, acipimox, WAG 994, pramlintide (Symlin™), 20 AC 2993, nateglinide, aldose reductase inhibitors (e.g., zopolrestat), glycogen phosphorylase inhibitors, sorbitol dehydrogenase inhibitors, sodium-hydrogen exchanger type 1 (NHE-1) inhibitors and/or cholesterol biosynthesis inhibitors or cholesterol absorption inhibitors, especially a HMG-CoA reductase inhibitor (e.g., atorvastatin or the hemicalcium salt thereof), or a HMG-CoA synthase 25 inhibitor, or a HMG-CoA reductase or synthase gene expression inhibitor, a CETP inhibitor, a bile acid sequesterant, a fibrate, an ACAT inhibitor, a squalene synthetase inhibitor, an anti-oxidant or niacin. The compounds of the present invention may also be administered in combination with a naturally occurring compound that acts to lower plasma cholesterol levels.

30 Such naturally occurring compounds are commonly called nutraceuticals and include, for example, garlic extract, *Hoodia* plant extracts, and niacin.

The dosage of the additional pharmaceutical agent (e.g., anti-obesity agent) will also be generally dependent upon a number of factors including the health of the subject being treated, the extent of treatment desired, the nature and kind of concurrent therapy, if any, and the frequency of treatment 5 and the nature of the effect desired. In general, the dosage range of an anti-obesity agent is in the range of from about 0.001 mg to about 100 mg per kilogram body weight of the individual per day, preferably from about 0.1 mg to about 10 mg per kilogram body weight of the individual per day. However, some variability in the general dosage range may also be required depending 10 upon the age and weight of the subject being treated, the intended route of administration, the particular anti-obesity agent being administered and the like. The determination of dosage ranges and optimal dosages for a particular patient is also well within the ability of one of ordinary skill in the art having the benefit of the instant disclosure.

15 As discussed above, the compounds of the present invention are useful for treating diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists; therefore, another embodiment of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention and a 20 pharmaceutically acceptable excipient, diluent or carrier. Alternatively, a compound of the present invention may be administered in combination with at least one additional pharmaceutical agent (referred to herein as a "combination") which is also preferably administered in the form of a pharmaceutical composition. A compound of the present invention or a 25 combination can be administered in any conventional oral, rectal, transdermal, parenteral, (for example, intravenous, intramuscular, or subcutaneous) intracisternal, intravaginal, intraperitoneal, intravesical, local (for example, powder, ointment or drop), or buccal, or nasal, dosage form. In the combination aspect of the invention, the compound of the present invention 30 and at least one other pharmaceutical agent (e.g., anti-obesity agent described above) may be administered either separately or in the

pharmaceutical composition comprising both. It is generally preferred that such administration be oral. However, if the subject being treated is unable to swallow, or oral administration is otherwise impaired or undesirable, parenteral or transdermal administration may be appropriate.

- 5 When a combination is administered, such administration can be sequential in time or simultaneous with the simultaneous method being generally preferred. For sequential administration, the combination can be administered in any order. It is generally preferred that such administration be oral. It is especially preferred that such administration be oral and
10 simultaneous. When the combination is administered sequentially, the administration of the compound of the present invention and the additional pharmaceutical agent can be by the same or by different methods.

A typical formulation is prepared by mixing a compound of the present invention and a excipient, diluent or carrier. Suitable excipients, diluents and
15 carriers are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble and/or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, and the like. The particular excipient, diluent or carrier used will depend upon the means and purpose for which the compound of the present invention is being
20 applied. Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal. In general, safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene
25 glycols (e.g., PEG400, PEG300), etc. and mixtures thereof. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to
30 provide an elegant presentation of the drug (i.e., a compound of the present

invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of 5 the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)) is dissolved in a suitable solvent in the presence of one or more of the excipients described above. The dissolution rate of poorly water-soluble compounds may be enhanced by the use of a spray-dried dispersion, such as those described by 10 Takeuchi, H., et al. in "Enhancement of the dissolution rate of a poorly water-soluble drug (tolbutamide) by a spray-drying solvent deposition method and disintegrants" *J. Pharm. Pharmacol.*, 39, 769-773 (1987).

Compositions suitable for parenteral injection generally include pharmaceutically acceptable sterile aqueous or nonaqueous solutions, 15 dispersions, suspensions, or emulsions. The compositions generally include sterile excipients, diluents or carriers for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous excipients, diluents or carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, 20 vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, 25 wetting, emulsifying, and dispersing agents. Prevention of microorganism contamination of the compositions can be accomplished with various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged 30 absorption of injectable pharmaceutical compositions can be brought about by

the use of agents capable of delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, powders, and granules. In such solid dosage forms, a compound of the present invention or a combination is admixed with at least one pharmaceutically acceptable excipient, diluent or carrier. Suitable excipients, diluents, or carriers include sodium citrate or dicalcium phosphate, or (a) fillers or extenders (e.g., starches, lactose, sucrose, mannitol, silicic acid and the like); (b) binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, acacia and the like); (c) humectants (e.g., glycerol and the like); (d) disintegrating agents (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, sodium carbonate and the like); (e) solution retarders (e.g., paraffin and the like); (f) absorption accelerators (e.g., quaternary ammonium compounds and the like); (g) wetting agents (e.g., cetyl alcohol, glycerol monostearate and the like); (h) adsorbents (e.g., kaolin, bentonite and the like); and/or (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and the like). In the case of capsules and tablets, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be used as fillers in soft or hard filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.

Solid dosage forms such as tablets, dragees, capsules, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may also contain opacifying agents, and can also be of such composition that they release the compound of the present invention and/or the additional pharmaceutical agent in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The drug can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the compound of the present invention or the combination, the liquid dosage form may contain excipients, diluents or carriers. Suitable excipients, 5 diluents or carriers include additives such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame seed 10 oil and the like), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, or mixtures of these substances, and the like. Other suitable additives (i.e., excipients, diluents or carriers) include wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

15 Suspensions, in addition to the compound of the present invention or the combination, may further comprise suspending agents, e.g., ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances, and the like.

20 Compositions for rectal or vaginal administration preferably comprise suppositories, which can be prepared by mixing a compound of the present invention or a combination with suitable non-irritating excipients, diluents, or carriers, such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ordinary room temperature but liquid at body temperature and 25 therefore melt in the rectum or vaginal cavity thereby releasing the active component(s).

30 Dosage forms for topical administration of the compounds of the present invention and combinations of the compounds of the present invention with anti-obesity agents may comprise ointments, powders, sprays and inhalants. The drugs are admixed under sterile condition with a pharmaceutically acceptable excipient, diluent or carrier, and any

preservatives, buffers, or propellants that may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also intended to be included within the scope of the present invention.

The compound of the present invention or combination is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product. The pharmaceutical composition (or formulation) for application may then be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.

The following paragraphs describe exemplary formulations, dosages, etc. useful for non-human animals. The administration of a compound of the present invention or combination (i.e., a compound of the present invention with at least one additional pharmaceutical agent) can be effected orally or non-orally (e.g., by injection).

An amount of a compound of the present invention (or combination) is administered such that an effective dose is received. Generally, a daily dose that is administered orally to an animal is between about 0.01 and about 1,000 mg/kg of body weight, preferably between about 0.01 and about 300 mg/kg of body weight.

Conveniently, a compound of the present invention (or combination) can be carried in the drinking water so that a therapeutic dosage of the compound is ingested with the daily water supply. The compound can be directly metered into drinking water, preferably in the form of a liquid, water-

soluble concentrate (such as an aqueous solution of a water-soluble salt).

Conveniently, a compound of the present invention (or combination) can also be added directly to the feed, as such, or in the form of an animal feed supplement, also referred to as a premix or concentrate. A premix or
5 concentrate of the compound with an excipient, diluent or carrier is more commonly employed for the inclusion of the agent in the feed. Suitable carriers are liquid or solid, as desired, such as water, various meals such as alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, corn cob meal and corn meal, molasses, urea, bone meal, and mineral mixes such as
10 are commonly employed in poultry feeds. A particularly effective carrier is the respective animal feed itself; that is, a small portion of such feed. The carrier facilitates uniform distribution of the compound in the finished feed with which the premix is blended. Preferably, the compound is thoroughly blended into the premix and, subsequently, the feed. In this respect, the compound may
15 be dispersed or dissolved in a suitable oily vehicle such as soybean oil, corn oil, cottonseed oil, and the like, or in a volatile organic solvent and then blended with the carrier. It will be appreciated that the proportions of compound in the concentrate are capable of wide variation since the amount of the compound in the finished feed may be adjusted by blending the
20 appropriate proportion of premix with the feed to obtain a desired level of compound.

High potency concentrates may be blended by the feed manufacturer with proteinaceous carrier such as soybean oil meal and other meals, as described above, to produce concentrated supplements, which are suitable
25 for direct feeding to animals. In such instances, the animals are permitted to consume the usual diet. Alternatively, such concentrated supplements may be added directly to the feed to produce a nutritionally balanced, finished feed containing a therapeutically effective level of a compound of the present invention. The mixtures are thoroughly blended by standard procedures, such
30 as in a twin shell blender, to ensure homogeneity.

If the supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the compound across the top of the dressed feed.

Drinking water and feed effective for increasing lean meat deposition
5 and for improving lean meat to fat ratio are generally prepared by mixing a compound of the present invention with a sufficient amount of animal feed to provide from about 10^{-3} to about 500 ppm of the compound in the feed or water.

The preferred medicated swine, cattle, sheep and goat feed generally
10 contain from about 1 to about 400 grams of a compound of the present invention (or combination) per ton of feed, the optimum amount for these animals usually being about 50 to about 300 grams per ton of feed.

The preferred poultry and domestic pet feeds usually contain about 1 to about 400 grams and preferably about 10 to about 400 grams of a compound
15 of the present invention (or combination) per ton of feed.

For parenteral administration in animals, the compounds of the present invention (or combination) may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean
20 meat to fat ratio is sought.

In general, parenteral administration involves injection of a sufficient amount of a compound of the present invention (or combination) to provide the animal with about 0.01 to about 20 mg/kg/day of body weight of the drug. The preferred dosage for poultry, swine, cattle, sheep, goats and domestic
25 pets is in the range of from about 0.05 to about 10 mg/kg/day of body weight of drug.

Paste formulations can be prepared by dispersing the drug in a pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like.

30 Pellets containing an effective amount of a compound of the present invention, pharmaceutical composition, or combination can be prepared by

admixing a compound of the present invention or combination with a diluent such as carbowax, caruba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process.

5 It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level which will provide the increase in lean meat deposition and improvement in lean meat to fat ratio desired. Moreover, implants may also be made periodically during the animal treatment period in order to maintain the proper drug level in the animal's
10 body.

The present invention has several advantageous veterinary features. For the pet owner or veterinarian who wishes to increase leanness and/or trim unwanted fat from pet animals, the instant invention provides the means by which this may be accomplished. For poultry, beef, and swine breeders,
15 utilization of the method of the present invention yields leaner animals that command higher sale prices from the meat industry.

Embodiments of the present invention are illustrated by the following Examples. It is to be understood, however, that the embodiments of the invention are not limited to the specific details of these Examples, as other
20 variations thereof will be known, or apparent in light of the instant disclosure, to one of ordinary skill in the art.

EXAMPLES

Unless specified otherwise, starting materials are generally available
25 from commercial sources such as Aldrich Chemicals Co. (Milwaukee, WI), Lancaster Synthesis, Inc. (Windham, NH), Acros Organics (Fairlawn, NJ), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, NJ), and AstraZeneca Pharmaceuticals (London, England).

General Experimental Procedures

30 Unless stated otherwise: all operations were carried out at room or ambient temperature, that is, in the range of 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure with a bath

of up to 60°C; reactions were monitored by thin layer chromatography (tlc) and reaction times are given for illustration only; melting points (m.p.) given are uncorrected (polymorphism may result in different melting points); structure and purity of all isolated compounds were assured by at least one of 5 the following techniques: TLC (Merck silica gel 60 F-254 precoated plates), high performance liquid chromatography (HPLC), mass spectrometry, nuclear magnetic resonance (NMR) or infrared spectroscopy (IR). Yields are given for illustrative purposes only.

Flash column chromatography was carried out using Merck silica gel 10 60 (230-400 mesh ASTM). Low-resolution mass spectral data (EI) were obtained on a Automass 120 (JEOL) mass spectrometer. Liquid Chromatography data was collected on a Hewlett Packard 1100 Liquid Chromatography/ Mass Selective Detector (LC/MSD). Analysis was performed on a Luna C-18 column with dimensions of 3.0x150 mm. The flow 15 rate was 0.425 ml/minute running a gradient of 50% 0.1% aqueous formic acid and 50% acetonitrile to 100% acetonitrile in 15 minutes. The ionization type for the mass detector of the Mass Spectrophotometer was atmospheric pressure electrospray in the positive ion mode with a fragmentor voltage of 50 volts.

NMR data was determined at 400 MHz (Varian Enova 400 Mhz 20 spectrometer) using deuterated chloroform (99.8% D), methanol (99.8% D) or dimethylsulfoxide (99.9% D) as solvent unless indicated otherwise, relative to tetramethylsilane (TMS) as internal standard in parts per million (ppm); conventional abbreviations used are: s = singlet, d = doublet, t = triplet, q = 25 quartet, m = multiplet, br = broad, etc.


The following abbreviations are used:

THF:	tetrahydrofuran
CH ₂ Cl ₂ :	dichloromethane (DCM)
NaHCO ₃ :	sodium bicarbonate
HCl:	hydrogen chloride
MgSO ₄ :	magnesium sulfate

	Na ₂ SO ₄ :	sodium sulfate
	DME:	dimethoxyethane
	n-BuLi:	n-butyllithium
	DMF:	dimethylformamide
5	DCE:	dichloroethane

Preparation of Key Intermediates

Preparation of Intermediate 5-Chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester (I-1a):




10 (I-1a)

A mixture of 2-dichlorophenyl hydrazine hydrochloride (13.4 g, 75 mmol) and diethylacetylene dicarboxylate (12.0 ml, 75 mmol) in dry ethanol (200 ml) was treated with K₂CO₃ (20.7 g, 150 mmol) and the resulting slurry 15 mixture was heated at reflux for 5 hours. The reaction mixture was cooled to room temperature, concentrated down to about 150 ml, and acidified with 1N HCl (~100 ml). Addition of H₂O (350 ml) resulted in the formation of orange precipitate which was collected by filtration and dried in an oven overnight to yield the product, 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3- 20 carboxylic acid ethyl ester I-1a (17.4g, 87%): ¹H NMR (400 MHz, CD₃OD) δ 7.62 – 7.46 (m, 4H), 6.00 (s, 1H), 4.35 (q, 2H), 1.36 (t, 3H); MS (m/z) 267.3 (M+); HPLC (method A): retention time: 1.7 minutes

Preparation of Intermediate 5-Chloro-1-(2-chloro-phenyl)-4-formyl-1H-


pyrazole-3-carboxylic acid ethyl ester (I-1b):



(I-1b)

N,N-dimethylformamide (5.14 ml, 4 equiv) was added slowly to a phosphorus oxychloride (100 ml) solution of 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester (I-1a, 16.37 g, 61.38 mmol) at room temperature. The resulting solution was refluxed for 24 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, concentrated down to ~50 ml, quenched with 800 ml of ice water (CAUTION: significant heat and gas evolution occurred), and extracted with ethyl acetate (3x300ml). The combined organic extracts were dried and concentrated under vacuum to give the crude product. Silica gel purification with a solvent gradient of 15% to 20% acetone:hexane provided the desired product, 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester I-1b, as a waxy yellow solid (7.96 g, 41%): ^1H NMR (400 MHz, CDCl_3) δ 10.53 (s, 1H), 7.58 – 7.39 (m, 4H), 6.05 (s, 1H), 4.49 (q, 2H), 1.42 (t, 3H); MS (m/z) 314.1 (M+H); HPLC: retention time (RT): 2.4 minutes.

Preparation of Intermediate 4-(tert-Butoxycarbonyl-hydrazonomethyl)-5-chloro-1-(2-chloro-phenyl)-1H-pyrazole-3-carboxylic acid ethyl ester (I-1c):




(I-1c)

A mixture of the 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester (I-1b, 13.5 g, 43.2 mmol) and t-butyl carbazate

- 5 (hydrazinecarboxylic acid tert-butyl ester, 5.7g, 43.2 mmol) in dry ethanol was heated under reflux for 17 hours. After the reaction mixture was cooled to room temperature, a white solid precipitated out of solution. The solid was collected by filtration while washing with cold ethanol and dried under vacuum to provide the desired product, 4-(tert-butoxycarbonyl-hydrazonomethyl)-5-
10 chloro-1-(2-chloro-phenyl)-1H-pyrazole-3-carboxylic acid ethyl ester I-1c (8.28 g, 93%); ¹H NMR (400 MHz, CDCl₃) δ 8.48 (br s, 1H), 8.12 (br s, 1H), 7.55 – 7.39 (m, 4H), 4.42 (q, 2H), 1.51 (s, 9H), 1.39 (t, 3H); MS (m/z) 427.1 (M+); HPLC: retention time (RT): 2.8 minutes.

- 15 Preparation of Intermediate 3-Chloro-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (I-1d):




(I-1d)

A slurry of 4-(tert-butoxycarbonyl-hydrazone)methyl)-5-chloro-1-(2-chloro-phenyl)-1H-pyrazole-3-carboxylic acid ethyl ester (I-1c, 13.5 g, 31.6 mmol) in acetic acid (200 ml) was heated under reflux for 17 hours. As the reaction mixture was cooled to room temperature, a white solid precipitated 5 out of solution. This solid was collected by filtration and dried to provide 3-chloro-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one I-1d (8.28 g, 93%): ¹H NMR (400 MHz, CD₃OD) δ 8.48 (br s, 1H), 8.12 (br s, 1H), 7.55 – 7.39 (m, 4H), 4.42 (q, 2H), 1.51 (s, 9H), 1.39 (t, 3H); MS (m/z) 281.1 (M+); HPLC: retention time (RT): 1.7 min.

10

Preparation of Intermediate 2-(2-Chloro-phenyl)-3-(4-fluoro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (I-1e-1):



15 (I-1e-1)


A slurry of the 3-chloro-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (I-1d, 788.8, 2.81 mmol), p-fluorobenzeneboronic acid (550 mg, 3.93 mmol), palladium tetrakis(triphenylphosphine) (162 mg, 0.14 mmol), and aqueous K₂CO₃ (2M, 4.2 ml, 3 equiv) in 16:1 toluene:ethanol (23.4 ml) 20 was heated under a N₂ atmosphere at ~80°C for 17 h and at ~100°C for 6 h. The reaction was cooled to room temperature, diluted with 1N aqueous HCl (20 ml), and extracted with CH₂Cl₂ (3x20 ml). The combined organic extracts were concentrated *in vacuo* until a yellow precipitate was formed. The solid 25 was collected by filtration to provide 2-(2-chloro-phenyl)-3-(4-fluoro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one I-1e-1 (846.9 mg, 89%): ¹H NMR

(400 MHz, CDCl₃) δ 9.80 (br s, 1H), 8.15 (s, 1H), 7.55 – 7.40 (m, 3H), 7.29 (m, 2H), 7.10 (t, 2H); MS (m/z) 341.2 (M⁺); HPLC: retention time (RT): 2.1 min.

The following intermediates were prepared according to the procedure
5 described above:

Example No	Compound	MS	HPLC Ret Time
I-1e-2	2-(2-Chloro-phenyl)-3-phenyl-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one	323.2	2.0
I-1e-3	2-(2-Chloro-phenyl)-3-p-tolyl-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one	337.2	2.2

Preparation of Intermediate 3-(4-Chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (I-1e-4):




10

(I-1e-4)

A solution of 6-benzyl-3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (Example 1A-2, 303 mg, 0.68 mmol) in
15 dry toluene (2.5 ml) was treated with aluminum chloride (1.36 ml of 2M
solution in nitrobenzene, 1.4 mmol). The reaction mixture was heated at 80°C
for 14 hours, cooled to room temperature, poured into saturated aqueous
NaHCO₃ (20 ml), and extracted with EtOAc (3x10 ml). The combined organic
extracts were dried and concentrated under vacuum. Hexanes were added to
20 the nitrobenzene residue until a light brown solid precipitated out of solution.

The solid was collected by filtration and dried under vacuum to give the product, 3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one **I-1e-4** (218 mg, 90%): ^1H NMR (400 MHz, CDCl_3) δ 9.80 (br s, 1H), 8.18 (br s, 1H), 7.55 – 7.43 (m, 4H), 7.39 (d, 2H), 7.23 (d, 2H); MS (m/z) 357.2 (M^+); HPLC: retention time (RT): 2.3 minutes.


Preparation of Intermediate 5-Chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid (I-2a):



(I-2a)

A mixture of the ester 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid ethyl ester (**I-1b**, 4.15 g, 13.3 mmol) and lithium hydroxide monohydrate (637 mg, 26.3 mmol) in 2:1 MeOH:H₂O (21 ml) was stirred vigorously at room temperature for 3 hours. The reaction mixture was acidified with 1 N aqueous HCl. A white solid precipitated out of solution and was collected by filtration and dried under vacuum to provide the product, 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid **I-2a** (3.79 g): ¹H NMR (400 MHz, CDCl₃) δ 10.05 (s, 1H), 7.63-7.55 (m, 2H), 7.51 (m, 2H); MS (m/z) 285.0 (M⁺); HPLC: retention time (RT): 1.5 minutes.


Preparation of Intermediate 6-Benzyl-3-chloro-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (I-2b):



(I-2b)

A slurry of 5-chloro-1-(2-chloro-phenyl)-4-formyl-1H-pyrazole-3-carboxylic acid (I-2a, 202 mg, 0.71 mmol) in CH₂Cl₂ (4 ml) under a N₂ atmosphere at room was treated with oxalyl chloride (0.081 ml, 0.85 mmol) and catalytic amount of DMF (2 drops). The reaction mixture was stirred at room temperature for 2 hours, at which time a homogenous solution was formed. The reaction mixture was concentrated under vacuum to provide a pale yellowish solid. This yellow solid was dissolved in CH₂Cl₂ (3 ml) at 0°C and a solution of benzylhydrazine dihydrochloride (152 mg, 0.78 mmol) and triethylamine (0.32 ml, 2.2 mmol) in CH₂Cl₂ (8 ml) was added *via* cannula. The reaction mixture was warmed to room temperature, stirred for 6 hours, and diluted with H₂O (20 ml). The organic layer was separated and the aqueous layer extracted once with EtOAc (20 ml). The combined organic solutions were dried (Na₂SO₄) and concentrated *in vacuo* to give an oily residue. Chromatography through a flash plug silica gel column using a solvent gradient of 100% CH₂Cl₂ to 5% EtOAc:CH₂Cl₂ provided the desired product, 6-benzyl-3-chloro-2-(2-chlorophenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one I-2b as a white solid (195 mg, 74%): ¹H NMR (400 MHz, CDCl₃) δ 8.12 (s, 1H), 7.62-7.51 (m, 2H), 7.48 (m, 4H), 7.32 (m, 2 H), 5.42 (s, 2H); MS (m/z) 371.0 (M+); HPLC: retention time (RT): 2.7 min.


Preparation of Intermediate 2-Chloro-N-(4-chloro-phenyl)-benzamidine (I-3a):



(I-3a)

Trimethylaluminum (2M in hexanes, 100 ml, 200 mmol) was added dropwise to a solution of 4-chloro-phenylamine (18.2 g, 143 mmol) in toluene (550 ml) under a N₂ atmosphere at 0°C. The reaction mixture was warmed to room temperature and stirred for 3.5 hours. A solution of 2-chlorobenzonitrile (23.6 g, 171 mmol) in toluene (140 ml) was slowly added. The heterogeneous mixture was heated at 80°C for 17 hours, cooled to room temperature, diluted with CHCl₃/methanol (2:1), and poured over a slurry of silica gel. The filter cake was washed with additional CH₂Cl₂/MeOH (2:1). The combined filtrates were concentrated *in vacuo*, and the resulting yellow solid was triturated with hexanes/ether (2:1). The product I-3a (25.1 g, 66%) was used without further purification.

15 Preparation of Intermediate 1-(4-Chlorophenyl)-2-(2-chlorophenyl)-4-hydroxy-4,5-dihydro-1H-imidazole-4-carboxylic acid ethyl ester (I-3b):




(I-3b)

A mixture of 2-chloro-N-(4-chlorophenyl)-benzamidine (I-3a, 25.1 g, 95 mmol) and NaHCO₃ (84 g, 189 mmol) in 2-propanol (473 ml) was treated with 3-bromo-2-oxo-propionic acid ethyl ester (14.3 ml, 22 g, 113 mmol). The reaction mixture was heated at 80 °C for 17 hours. After cooling to room temperature, the solvent was removed *in vacuo*. The residue was diluted with

CH_2Cl_2 and the organic solution was washed with H_2O , dried over MgSO_4 , and concentrated *in vacuo* to provide the product, 1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-4-hydroxy-4,5-dihydro-1*H*-imidazole-4-carboxylic acid ethyl ester I-3b as a dark red residue (36 g).


5

Preparation of 1-(4-Chloro-phenyl)-2-(2-chloro-phenyl)-1*H*-imidazole-4-carboxylic acid ethyl ester (I-3c):



(I-3c)


- 10 The crude 1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-4-hydroxy-4,5-dihydro-1*H*-imidazole-4-carboxylic acid ethyl ester (I-3b, 36 g, 94.7 mmol) obtained from the previous step and *p*-toluenesulfonic acid monohydrate (4.5 g, 24 mmol) in toluene (630 ml) was heated under reflux for 17 hours. The reaction mixture was cooled to room temperature and concentrated *in vacuo*.
- 15 The crude residue was taken up in CH_2Cl_2 and the organic solution was washed with H_2O , sat'd aq. NaHCO_3 , and saturated aqueous NaCl , dried over MgSO_4 , and concentrated *in vacuo*. The crude residue was purified by silica gel plug filtration using a solvent gradient of 2% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$ to 10% $\text{EtOAc}/\text{CH}_2\text{Cl}_2$. The fractions containing the product were concentrated, and
- 20 the oily residue was diluted with 1:3 $\text{EtOAc}/\text{hexanes}$ (200 ml). After 1 hour, a solid precipitated out of solution and was collected by filtration to provide 1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-1*H*-imidazole-4-carboxylic acid ethyl ester I-3c (18.63 g, 69.7%).
- 25 Preparation of 5-Bromo-1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-1*H*-imidazole-4-carboxylic acid ethyl ester (I-3d):



(I-3d)

Bromine (3.6 ml, 0.07 mol) was added to a solution of 1-(4-chlorophenyl)-2-(2-chlorophenyl)-1H-imidazole-4-carboxylic acid ethyl ester (I-3c, 5 3.6 g, 0.01 mol) in glacial acetic acid (50 ml) at room temperature. The reaction mixture was stirred for 17 hours, poured over ice-water, and treated with 25% aqueous NaOH until the orange solution turned a yellow color. The aqueous solution was extracted with CH₂Cl₂ (3x) and the combined extracts were dried and concentrated *in vacuo* to give the desired compound I-3d as 10 an oil (4.7 g): +APCI MS (M+1) 441.1; ¹H NMR (CD₃Cl) δ 1.41 (3H, t), 4.43 (2H, q), 7.08-7.12 (2H, m), 7.20 - 7.40 (7H, m).

Preparation of Intermediate 1-(4-Chloro-phenyl)-2-(2-chloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e-1):



15

(I-3e-1)

To a solution of 5-bromo-1-(4-chlorophenyl)-2-(2-chlorophenyl)-1H-imidazole-4-carboxylic acid ethyl ester (I-3d, 4.4 g, 0.01 mmol) in anhydrous THF (100 ml) at -78°C was slowly added *tert*-butyl lithium (13 ml of 1.7 M solution in pentane, 0.22 mol). After 1 hour, DMF (7.7 ml, 0.1 ml) was added dropwise. The reaction mixture was stirred at -78 °C for 2.5 hours, quenched

with saturated aqueous NH₄Cl (10 ml), allowed to slowly warm to room temperature, and finally poured into saturated aqueous NaCl. The aqueous solution was extracted with Et₂O (3x) and the combined organic extracts were dried (Na₂SO₄) and concentrated *in vacuo*. The crude residue was purified 5 via flash chromatography using a solvent gradient of 1:3 EtOAc/hexanes to 1:1 EtOAc/hexanes to give the desired product I-3e-1 as a pale yellow amorphous glass (2.0 g): +APCI MS (M+1) 389.2; ¹H NMR (CD₂Cl₂) δ 1.41 (3H, t), 4.45 (2H, q), 7.09-7.14 (2H, m), 7.24-7.39 (7H, m), 10.50 (1H, s).


10 The following intermediates were prepared by the procedures described above from the appropriately substituted arylamine and benzonitrile derivatives:

1-(4-Chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e-2);

15 2-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e-3); and

2-(4-Chloro-phenyl)-1-(2-chloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e-4).

20 Preparation of Intermediate 1-(4-Chloro-phenyl)-2-(2-chloro-phenyl)-5-hydrazonomethyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3f):




(I-3f)

25 A solution of 1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e, 102 mg, 0.26 mmol), aqueous hydrazine hydrate (50% solution, 0.6 mmol) and glacial acetic acid (1 drop)

was heated under reflux in toluene (3 ml) for 18 hours. After cooling to room temperature, the reaction mixture was concentrated *in vacuo*. The residue was partitioned between CH₂Cl₂ and saturated aqueous NaHCO₃. The organic solution was dried and concentrated *in vacuo*. Purification using 2 mm chromatotron plates and a solvent gradient of 1:1 EtOAc/hexanes to 5 100% EtOAc provided the desired product I-3f (R_f = 0.8, 100% EtOAc, 62 mg): +APCI MS (M+1) 403.1; ¹H NMR (CD₂Cl₂) δ 1.40 (3H, t), 4.37 (2H, q), 5.60 (2H, br s), 7.10-7.14 (2H, m), 7.21-7.25 (3H, m), 7.29-7.33 (3H, m), 8.40 (1H, s).

10

Preparation of Intermediate 2-(2-Chloro-phenyl)-1-(4-chloro-phenyl)-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one (I-3g):




(I-3g)

15 A solution of 1-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-hydrazonomethyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3f, 54 mg, 0.134 mmol) and glacial acetic acid (1 drop) in toluene (3 ml) was heated under reflux for 18 hours, at which time a white solid precipitated out of solution. The reaction mixture was cooled to room temperature and 20 concentrated *in vacuo*. The crude residue was purified *via* 1 mm chromatotron plates using 100% EtOAc as solvent to give the desired product I-3g as a white solid (22 mg): +APCI MS (M+1) 357.1; ¹H NMR (CD₂Cl₂) δ 7.18-7.48 (8H, m), 8.01 (1H, s), 10.60 (1H, s).

Example 1 illustrates the preparation of 2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one analogs having the general Formulae (I) and (III).

Example 1

Preparation of 3-(4-Chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2,2-trifluoro-ethyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (1A-1):




(1A-1)

A solution of 3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-
10 pyrazolo[3,4-d]pyridazin-7-one (1f-2, 150 mg, 0.42 mmol) in dry DMF (3 ml) at room temperature was treated with sodium hydride (19.3 mg of 60% oil disp., 0.5 mmol). After the reaction mixture was stirred for 0.5 hours, trifluoroethyl iodide (0.05 ml, 0.5 mmol) was added. The homogeneous solution was stirred for 17 hours, diluted with water (10 ml), and extracted with EtOAc (3 X 15 20 ml). The combined organic extracts were dried and concentrated *in vacuo* to provide crude product which was purified by preparative TLC (1000 µm, 1:1 EtOAc:hexane) to yield a pale white solid 1A-1 (43 mg, 23 %); ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 7.57–7.35 (m, 6H), 7.20 (d, 2H), 4.87 (q, 2H); MS (m/z) 439.2 (M+); HPLC: retention time (RT): 3.0 minutes

20

Preparation of 6-benzyl-3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (1A-2):




(1A-2)

A slurry of 6-benzyl-3-chloro-2-(2-chlorophenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one (1-2b, 1.01 g, 2.72 mmol), p-chlorobenzene-
5 boronic acid (595 mg, 3.81 mmol), palladium tetrakis(triphenylphosphine) (157 mg, 0.14 mmol), and aqueous 2 M K_2CO_3 (3 ml, 2.2 equiv) in 14.3:1 toluene/ethanol (21.4 ml) was heated under a nitrogen atmosphere at 110°C for 3 hours and at ~100°C for 4 hours. The reaction mixture was cooled to room temperature, diluted with water (20 ml), and extracted with CH_2Cl_2 (3X20 ml). The combined organic extracts were dried and concentrated *in vacuo* to give a brownish oil. Flash gel chromatography using a solvent gradient of 100% hexanes to 95% hexanes/EtOAc provided 1A-2 as pale light yellow solid (1.18 g, 97%). 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1H), 7.54-7.17 (m, 13H), 7.48 (m, 4H), 5.46 (s, 2H); MS (m/z) 357.2 (M+); HPLC:
10 retention time (RT): 2.3 min.
15

Example 2

Preparation of 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one (2A-1):



(2A-1)

A solution of 1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-formyl-1H-imidazole-4-carboxylic acid ethyl ester (I-3e-2, 18 mg, 0.042 mmol),
5 ethylhydrazine oxalate (15 mg, 0.1 mmol), and NEt₃ (28 microliters, 0.2 mmol)
in EtOH (1 ml) was heated at 85°C for 17 hours. The reaction mixture was
cooled to room temperature and concentrated under vacuum. The residue
was dissolved in toluene (1 ml), catalytic p-TsOH (1-2 mg) was added, and
the solution was heated under reflux for 93 h. The reaction mixture was
10 diluted with 1 M K₂CO₃, the organic layer was separated, and the aqueous
solution was extracted with EtOAc. The combined organic solutions were
washed with sat'd aqueous NaCl, dried, and concentrated *in vacuo*. The
crude residue was purified on a chromatotron (1 mm plates) using 50%
EtOAc/hexanes as a solvent to give 1-(4-chloro-phenyl)-2-(2,4-dichloro-
15 phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one 2A-1 as an
amorphous solid (9 mg); ¹H NMR (400 MHz, CD₂Cl₂) δ 7.98 (s, 1H), 7.50 - 7.40
(m, 4H), 7.38 - 7.34 (m, 1H), 7.20 - 7.15 (m, 2H), 4.40 - 4.30 (m, 2H), 1.43 -
1.38 (m, 3H); MS (m/z) 419.1(M⁺).

20 The compounds listed in Tables 2 below were prepared using
procedures analogous to those described above for the synthesis of
Compound 2A-1 using the appropriate starting materials which are available
commercially, prepared using preparations well-known to those skilled in the
art, or prepared in a manner analogous to routes described above for other

intermediates. The compounds listed below were generally isolated as their free base and then converted to their corresponding hydrochloride salt prior to *in vivo* testing (if tested *in vivo*).

Table 2

Example No.	Compound	MS (M+H)
2A-2	2-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one	419.1
2A-3	2-(4-Chloro-phenyl)-1-(2-chloro-phenyl)-5-cyclohexyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one	439.3
2A-4	5-Benzyl-2-(4-chloro-phenyl)-1-(2-chloro-phenyl)-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one	447.2

5

PHARMACOLOGICAL TESTING

The utility of the compounds of the present invention in the practice of the instant invention can be evidenced by activity in at least one of the protocols described hereinbelow. The following acronyms are used in the 10 protocols described below.

BSA - bovine serum albumin

DMSO - dimethylsulfoxide

EDTA - ethylenediamine tetracetic acid

PBS – phosphate-buffered saline

15 EGTA - ethylene glycol-bis(β-aminoethyl ether) N,N,N',N'-tetraacetic acid

GDP - guanosine diphosphate

sc - subcutaneous

po - orally

20 ip - intraperitoneal

icv - intra cerebro ventricular

iv - intravenous

[³H]SR141716A - radiolabeled N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride available from Amersham Biosciences, Piscataway, NJ.

[³H]CP-55940 - radiolabeled 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-

- 5 hydroxypropyl)-cyclohexyl]-phenol available from NEN Life Science Products, Boston, MA.

AM251 - N -(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide available from Tocris™, Ellisville, MO.

- 10 All of the compounds listed in the Example section above were tested in the CB-1 receptor binding assay below. The compounds in the Examples provided a range of binding activities from 5 to 300 nM.

- 15 Selected compounds having an activity <20 nM were then tested in the CB-1 GTPγ [³⁵S] Binding Assay and the CB-2 binding assay described below in the Biological Binding Assays section. Selected compounds were then tested *in vivo* using one or more of the functional assays described in the Biological Functional Assays section below.

In Vitro Biological Assays

- Bioassay systems for determining the CB-1 and CB-2 binding properties and pharmacological activity of cannabinoid receptor ligands are described by Roger G. Pertwee in "Pharmacology of Cannabinoid Receptor Ligands" Current Medicinal Chemistry, 6, 635-664 (1999) and in WO 92/02640 (U.S. Application No. 07/564,075 filed August 8, 1990, incorporated herein by reference).

- 25 The following assays were designed to detect compounds that inhibit the binding of [³H] SR141716A (selective radiolabeled CB-1 ligand) and [³H] 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)-cyclohexyl]-phenol; radiolabeled CB-1/CB-2 ligand) to their respective receptors.

Rat CB-1 Receptor Binding Protocol

- PelFreeze brains (available from Pel Freeze Biologicals, Rogers, Arkansas) were cut up and placed in tissue preparation buffer (5 mM Tris HCl, pH = 7.4 and 2 mM EDTA), polytroned at high speed and kept on ice for 15

minutes. The homogenate was then spun at 1,000 X g for 5 minutes at 4°C. The supernatant was recovered and centrifuged at 100,000 X G for 1 hour at 4°C. The pellet was then re-suspended in 25 ml of TME (25 mM Tris, pH = 7.4, 5 mM MgCl₂, and 1 mM EDTA) per brain used. A protein assay was 5 performed and 200 µl of tissue totaling 20 µg was added to the assay.

The test compounds were diluted in drug buffer (0.5% BSA, 10% DMSO and TME) and then 25 µl were added to a deep well polypropylene plate. [³H] SR141716A was diluted in a ligand buffer (0.5% BSA plus TME) and 25 µl were added to the plate. A BCA protein assay was used to 10 determine the appropriate tissue concentration and then 200 µl of rat brain tissue at the appropriate concentration was added to the plate. The plates were covered and placed in an incubator at 20°C for 60 minutes. At the end of the incubation period 250 µl of stop buffer (5% BSA plus TME) was added to the reaction plate. The plates were then harvested by Skatron onto GF/B 15 filtermats presoaked in BSA (5 mg/ml) plus TME. Each filter was washed twice. The filters were dried overnight. In the morning the filters were counted on a Wallac Betaplate™ counter (available from PerkinElmer Life Sciences™, Boston, MA).

Human CB-1 Receptor Binding Protocol

20 Human embryonic kidney 293 (HEK 293) cells transfected with the CB-1 receptor cDNA (obtained from Dr. Debra Kendall, University of Connecticut) were harvested in homogenization buffer (10 mM EDTA, 10 mM EGTA, 10 mM Na Bicarbonate, protease inhibitors; pH = 7.4), and homogenized with a Dounce Homogenizer. The homogenate was then spun at 1,000X g for 5 25 minutes at 4°C. The supernatant was recovered and centrifuged at 25,000X G for 20 minutes at 4°C. The pellet was then re-suspended in 10 ml of homogenization buffer and re-spun at 25,000X G for 20 minutes at 4°C. The final pellet was re-suspended in 1 ml of TME (25 mM Tris buffer (pH = 7.4) containing 5 mM MgCl₂ and 1 mM EDTA). A protein assay was performed 30 and 200 µl of tissue totaling 20 µg was added to the assay.

The test compounds were diluted in drug buffer (0.5% BSA, 10% DMSO and TME) and then 25 µl were added to a deep well polypropylene plate. [³H] SR141716A was diluted in a ligand buffer (0.5% BSA plus TME) and 25 µl were added to the plate. The plates were covered and placed in an 5 incubator at 30°C for 60 minutes. At the end of the incubation period 250 µl of stop buffer (5% BSA plus TME) was added to the reaction plate. The plates were then harvested by Skatron onto GF/B filtermats presoaked in BSA (5 mg/ml) plus TME. Each filter was washed twice. The filters were dried overnight. In the morning the filters were counted on a Wallac Betaplate™ 10 counter (available from PerkinElmer Life Sciences™, Boston, MA).

CB-2 Receptor Binding Protocol

Chinese hamster ovary-K1 (CHO-K1) cells transfected with CB-2 cDNA (obtained from Dr. Debra Kendall, University of Connecticut) were harvested in tissue preparation buffer (5 mM Tris-HCl buffer (pH = 7.4) containing 2 mM 15 EDTA), polytroned at high speed and kept on ice for 15 minutes. The homogenate was then spun at 1,000X g for 5 minutes at 4°C. The supernatant was recovered and centrifuged at 100,000X G for 1 hour at 4°C. The pellet was then re-suspended in 25 ml of TME (25 mM Tris buffer (pH = 7.4) containing 5 mM MgCl₂ and 1 mM EDTA) per brain used. A protein 20 assay was performed and 200 µl of tissue totaling 10 µg was added to the assay.

The test compounds were diluted in drug buffer (0.5% BSA, 10% DMSO, and 80.5% TME) and then 25 µl were added to the deep well polypropylene plate. [³H] 5-(1,1-Dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy- 25 propyl)-cyclohexyl]-phenol was diluted a ligand buffer (0.5% BSA and 99.5% TME) and then 25 µl were added to each well at a concentration of 1 nM. A BCA protein assay was used to determine the appropriate tissue concentration and 200 µl of the tissue at the appropriate concentration was added to the plate. The plates were covered and placed in an incubator at 30 30°C for 60 minutes. At the end of the incubation period 250 µl of stop buffer (5% BSA plus TME) was added to the reaction plate. The plates were then

harvested by Skatron format onto GF/B filtermats presoaked in BSA (5 mg/ml) plus TME. Each filter was washed twice. The filters were dried overnight. The filters were then counted on the Wallac Betaplate™ counter.

CB-1 GTP γ [³⁵S] Binding Assay

5 Membranes were prepared from CHO-K1 cells stably transfected with the human CB-1 receptor cDNA. Membranes were prepared from cells as described by Bass et al, in "Identification and characterization of novel somatostatin antagonists," *Molecular Pharmacology*, **50**, 709-715 (1996).
10 GTP γ [³⁵S] binding assays were performed in a 96 well FlashPlate™ format in duplicate using 100 pM GTP γ [³⁵S] and 10 µg membrane per well in assay
buffer composed of 50 mM Tris HCl, pH 7.4, 3 mM MgCl₂, pH 7.4, 10 mM
MgCl₂, 20 mM EGTA, 100 mM NaCl, 30 µM GDP, 0.1 % bovine serum
albumin and the following protease inhibitors: 100 µg/ml bacitracin, 100 µg/ml
benzamidine, 5 µg/ml aprotinin, 5 µg/ml leupeptin. The assay mix was then
15 incubated with increasing concentrations of antagonist (10⁻¹⁰ M to 10⁻⁵ M) for 10 minutes and challenged with the cannabinoid agonist 5-(1,1-dimethyl-
heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol (10 µM). Assays
were performed at 30°C for one hour. The FlashPlates™ were then
centrifuged at 2000Xg for 10 minutes. Stimulation of GTP γ [³⁵S] binding was
20 then quantified using a Wallac Microbeta. EC₅₀ calculations were performed
using Prism™ by Graphpad.

Inverse agonism was measured in the absence of agonist using the protocol described above.

CB-1 FLIPR-based Functional Assay Protocol

25 CHO-K1 cells co-transfected with the human CB-1 receptor cDNA.
(obtained from Dr. Debra Kendall, University of Connecticut) and the
promiscuous G-protein G16 were used for this assay. Cells were plated 48
hours in advance at 12500 cells per well on collagen coated 384 well black
clear assay plates. Cells were incubated for one hour with 4µM Fluo-4 AM
30 (Molecular Probes) in DMEM (Gibco) containing 2.5 mM probenicid and
pluronic acid (.04%). The plates were then washed 3 times with HEPES-

buffered saline (containing probenicid; 2.5 mM) to remove excess dye. After 20 min the plates were added to the FLIPR individually and fluorescence levels was continuously monitored over an 80 s period. Compound additions were made simultaneously to all 384 wells after 20 s of baseline. Assays were 5 performed in triplicate and 6 point concentration-response curves generated. Antagonist compounds were subsequently challenged with 3 μ M WIN 55,212-2 (agonist). Data were analyzed using Graph Pad Prism.

Detection of Inverse Agonists

The following cyclic-AMP assay protocol using intact cells was used to 10 determine inverse agonist activity.

Cells were plated into a 96-well plate at a plating density of 10,000-14,000 cells per well at a concentration of 100 μ l per well. The plates were incubated for 24 hours in a 37°C incubator. The media was removed and media lacking serum (100 μ l) was added. The plates were then incubated for 15 18 hours at 37°C.

Serum free medium containing 1 mM IBMX was added to each well followed by 10 μ l of test compound (1:10 stock solution (25 mM compound in DMSO) into 50% DMSO/PBS) diluted 10X in PBS with 0.1% BSA. After incubating for 20 minutes at 37°C, 2 μ M of Forskolin was added and then 20 incubated for an additional 20 minutes at 37°C. The media was removed, 100 μ l of 0.01N HCl was added and then incubated for 20 minutes at room temperature. Cell lysate (75 μ l) along with 25 μ l of assay buffer (supplied in FlashPlate™ cAMP assay kit available from NEN Life Science Products Boston, MA) into a Flashplate. cAMP standards and cAMP tracer were added 25 following the kit's protocol. The flashplate was then incubated for 18 hours at 4°C. The content of the wells were aspirated and counted in a Scintillation counter.

In Vivo Biological Assays

Cannabinoid agonists such as Δ^9 -tetrahydrocannabinol (Δ^9 -THC) and 30 5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol have been shown to affect four characteristic behaviors in mice, collectively

known as the Tetrad. For a description of these behaviors see: Smith, P.B., et al. in "The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice." J. Pharmacol. Exp. Ther., 270(1), 219-227 (1994) and Wiley, J., et al. in "Discriminative stimulus effects of anandamide in rats," Eur. J. Pharmacol., 276(1-2), 49-54 (1995). Reversal of these activities in the Locomotor Activity, Catalepsy, Hypothermia, and Hot Plate assays described below provides a screen for *in vivo* activity of CB-1 antagonists.

All data are presented as % reversal from agonist alone using the following formula: (5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol/agonist - vehicle/agonist)/(vehicle/vehicle - vehicle/agonist). Negative numbers indicate a potentiation of the agonist activity or non-antagonist activity. Positive numbers indicate a reversal of activity for that particular test.

Locomotor Activity

Male ICR mice (n=6) (17-19 g, Charles River Laboratories, Inc., Wilmington, MA) were pre-treated with test compound (sc, po, ip, or icv). Fifteen minutes later, the mice were challenged with 5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol (sc). Twenty-five minutes after the agonist injection, the mice were placed in clear acrylic cages (431.8 cm x 20.9 cm x 20.3 cm) containing clean wood shavings. The subjects were allowed to explore surroundings for a total of about 5 minutes and the activity was recorded by infrared motion detectors (available from Coulbourn Instruments™, Allentown, PA) that were placed on top of the cages. The data was computer collected and expressed as "movement units."

Catalepsy

Male ICR mice (n=6)(17-19 g upon arrival) were pre-treated with test compound (sc, po, ip or icv). Fifteen minutes later, the mice were challenged with 5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol (sc). Ninety minutes post injection, the mice were placed on a 6.5 cm steel ring attached to a ring stand at a height of about 12 inches. The ring was mounted in a horizontal orientation and the mouse was suspended in the

gap of the ring with fore- and hind-paws gripping the perimeter. The duration that the mouse remained completely motionless (except for respiratory movements) was recorded over a 3-minute period.

The data were presented as a percent immobility rating. The rating
5 was calculated by dividing the number of seconds the mouse remains motionless by the total time of the observation period and multiplying the result by 100. A percent reversal from the agonist was then calculated.

Hypothermia

Male ICR mice (n=5) (17-19 g upon arrival) were pretreated with test
10 compounds (sc, po, ip or icv). Fifteen minutes later, mice were challenged with the cannabinoid agonist 5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol (sc). Sixty-five minutes post agonist injection, rectal body temperatures were taken. This was done by inserting a small thermostat probe approximately 2- 2.5 cm into the rectum.
15 Temperatures were recorded to the nearest tenth of a degree

Hot Plate

Male ICR mice (n=7) (17-19 g upon arrival) are pre-treated with test
compounds (sc, po, ip or iv). Fifteen minutes later, mice were challenged with
20 a cannabinoid agonist 5-(1,1-dimethyl-heptyl)-2-[5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol (sc). Forty-five minutes later, each mouse was tested for reversal of analgesia using a standard hot plate meter (Columbus Instruments). The hot plate was 10" x 10" x 0.75" with a surrounding clear acrylic wall. Latency to kick, lick or flick hindpaw or jump from the platform was recorded to the nearest tenth of a second. The timer was experimenter
25 activated and each test had a 40 second cut off. Data were presented as a percent reversal of the agonist induced analgesia.

Food Intake

The following screen was used to evaluate the efficacy of test
compounds for inhibiting food intake in Sprague-Dawley rats after an
30 overnight fast.

Male Sprague-Dawley rats were obtained from Charles River Laboratories, Inc. (Wilmington, MA). The rats were individually housed and fed powdered chow. They were maintained on a 12 hour light/dark cycle and received food and water *ad libitum*. The animals were acclimated to the vivarium for a period of one week before testing was conducted. Testing was completed during the light portion of the cycle.

To conduct the food intake efficacy screen, rats were transferred to individual test cages without food the afternoon prior to testing, and the rats were fasted overnight. After the overnight fast, rats were dosed the following morning with vehicle or test compounds. A known antagonist was dosed (3 mg/kg) as a positive control, and a control group received vehicle alone (no compound). The test compounds were dosed at ranges between 0.1 and 100 mg/kg depending upon the compound. The standard vehicle was 0.5% (w/v) methylcellulose in water and the standard route of administration was oral. However, different vehicles and routes of administration were used to accommodate various compounds when required. Food was provided to the rats 30 minutes after dosing and the Oxymax automated food intake system (Columbus Instruments, Columbus, Ohio) was started. Individual rat food intake was recorded continuously at 10-minute intervals for a period of two hours. When required, food intake was recorded manually using an electronic scale; food was weighed every 30 minutes after food was provided up to four hours after food was provided. Compound efficacy was determined by comparing the food intake pattern of compound-treated rats to vehicle and the standard positive control.

25 Alcohol Intake

The following protocol evaluates the effects of alcohol intake in alcohol preferring (P) female rats (bred at Indiana University) with an extensive drinking history. The following references provide detailed descriptions of P rats: Li ,T.-K., et al., "Indiana selection studies on alcohol related behaviors" 30 in Development of Animal Models as Pharmacogenetic Tools (eds McCleam C. E., Deitrich R. A. and Erwin V. G.), Research Monograph 6, 171-192

(1981) NIAAA, ADAMHA, Rockville, MD; Lumeng, L, et al., "New strains of rats with alcohol preference and nonpreference" Alcohol And Aldehyde Metabolizing Systems, 3, Academic Press, New York, 537-544 (1977); and Lumeng, L, et al., "Different sensitivities to ethanol in alcohol-preferring and -nonpreferring rats," Pharmacol, Biochem Behav., 16, 125-130 (1982).

Female rats were given 2 hours of access to alcohol (10% v/v and water, 2-bottle choice) daily at the onset of the dark cycle. The rats were maintained on a reverse cycle to facilitate experimenter interactions. The animals were initially assigned to four groups equated for alcohol intakes:

- 10 Group 1 – vehicle (n = 8); Group 2 – positive control (e.g., 5.6 mg/kg AM251; n = 8); Group 3 – low dose test compound (n = 8); and Group 4 – high dose of test compound (n = 8). Test compounds were generally mixed into a vehicle of 30% (w/v) β-cyclodextrin in distilled water at a volume of 1-2 ml/kg. Vehicle injections were given to all groups for the first two days of the experiment.
- 15 This was followed by 2 days of drug injections (to the appropriate groups) and a final day of vehicle injections. On the drug injection days, drugs were given sc 30 minutes prior to a 2-hour alcohol access period. Alcohol intake for all animals was measured during the test period and a comparison was made between drug and vehicle-treated animals to determine effects of the
- 20 compounds on alcohol drinking behavior.

Additional drinking studies were done utilizing female C57Bl/6 mice (Charles River). Several studies have shown that this strain of mice will readily consume alcohol with little to no manipulation required (see Middaugh et al., "Ethanol Consumption by C57BL/6 Mice: Influence of Gender and Procedural Variables" Alcohol, 17 (3), 175-183, 1999; Le et al., "Alcohol Consumption by C57BL/6, BALA/c, and DBA/2 Mice in a Limited Access Paradigm" Pharmacology Biochemistry and Behavior, 47, 375-378, 1994).

Mice (17-19 g) mice were individually housed upon arrival and given unlimited access to powdered rat chow, water and a 10 % (w/v) alcohol solution. After 2-3 weeks of unlimited access, water was restricted for 20 hours and alcohol was restricted to only 2 hours access daily. This was done in a

manner that the access period was the last 2 hours of the dark part of the light cycle.

Once drinking behavior stabilized, testing commenced. Mice were considered stable when the average alcohol consumption for 3 days was ± 5 20% of the average for all 3 days. Day 1 of test consisted of all mice receiving vehicle injection (sc or ip). Thirty to 120 minutes post injection access was given to alcohol and water. Alcohol consumption for that day was calculated (g/kg) and groups were assigned (n=7-10) so that all groups had equivocal alcohol intake. On day 2 and 3, mice were injected with vehicle or drug and the 10 same protocol as the previous day was followed. Day 4 was wash out and no injections were given. Data was analyzed using repeated measures ANOVA. Change in water or alcohol consumption was compared back to vehicle for each day of the test. Positive results would be interpreted as a compound that was able to significantly reduce alcohol consumption while having no effect on 15 water consumption.

Oxygen Consumption

Methods:

Whole body oxygen consumption is measured using an indirect calorimeter (Oxymax from Columbus Instruments, Columbus, OH) in male 20 Sprague Dawley rats (if another rat strain or female rats are used, it will be specified). Rats (300-380g body weight) are placed in the calorimeter chambers and the chambers are placed in activity monitors. These studies are done during the light cycle. Prior to the measurement of oxygen consumption, the rats are fed standard chow ad libitum. During the 25 measurement of oxygen consumption, food is not available. Basal pre-dose oxygen consumption and ambulatory activity are measured every 10 minutes for 2.5 to 3 hours. At the end of the basal pre-dosing period, the chambers are opened and the animals are administered a single dose of compound (the usual dose range is 0.001 to 10 mg/kg) by oral gavage (or other route of 30 administration as specified, i.e. s.c., i.p., i.v.). Drugs are prepared in methylcellulose, water or other specified vehicle (examples include PEG400, 30% beta-cyclo dextran and propylene glycol). Oxygen consumption and

ambulatory activity are measured every 10 minutes for an additional 1-6 hours post-dosing.

The Oxymax calorimeter software calculates the oxygen consumption (ml/kg/h) based on the flow rate of air through the chambers and difference in 5 oxygen content at inlet and output ports. The activity monitors have 15 infrared light beams spaced one inch apart on each axis, ambulatory activity is recorded when two consecutive beams are broken and the results are recorded as counts.

Resting oxygen consumption, during pre- and post-dosing, is 10 calculated by averaging the 10-min O₂ consumption values, excluding periods of high ambulatory activity (ambulatory activity count > 100) and excluding the first 5 values of the pre-dose period and the first value from the post-dose period. Change in oxygen consumption is reported as percent and is calculated by dividing the post-dosing resting oxygen consumption by the pre- 15 dose oxygen consumption *100. Experiments will typically be done with n = 4-6 rats and results reported are mean +/- SEM.


Interpretation:

An increase in oxygen consumption of >10% is considered a positive 20 result. Historically, vehicle-treated rats have no change in oxygen consumption from pre-dose basal.


CLAIMS

We claim:

1. A compound of Formula (I) or (II).



(I)



(II)

5

wherein

R^1 is an optionally substituted aryl or an optionally substituted heteroaryl;

R^2 is an optionally substituted aryl or an optionally substituted heteroaryl;

10 R^3 is hydrogen, (C_1 - C_4)alkyl optionally substituted with one or more substituents, or (C_1 - C_4)alkoxy; and

R^4 is a chemical moiety selected from the group consisting of (C_1 - C_9)alkyl, aryl, heteroaryl, aryl(C_1 - C_5)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C_1 - C_3)alkyl, 5-6 membered lactone, 5-15 to 6-membered lactam, and a 3- to 6-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

20 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

2. The compound of Claim 1 wherein said compound is a compound of Formula (I);
 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
 25 said compound or said salt.

3. The compound of Claim 2 wherein
R³ is hydrogen, (C₁-C₄)alkyl, or (C₁-C₄)alkyl optionally substituted with one or more fluorines; and

5 R⁴ is a chemical moiety selected from (C₁-C₉)alkyl, aryl(C₁-C₅)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring, or 3- to 6-membered partially or fully saturated heterocyclic ring, where the chemical moiety is optionally substituted with one or more substituents;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
10 the compound or the salt.

4. The compound of Claim 3 wherein

R³ is hydrogen or methyl;
R⁴ is fluoro-substituted (C₁-C₅)alkyl, aryl(C₁-C₅)alkyl, cyclopentyl,
15 cyclohexyl, pyranyl, furanyl, pyrrolidinyl, or piperidinyl;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

5. The compound of Claim 2, 3, or 4 wherein R¹ and R² are each
20 independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, halo-substituted (C₁-C₄)alkyl, and cyano;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

25
6. The compound of Claim 5 wherein R¹ and R² are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, fluoro-substituted (C₁-C₄)alkyl), and cyano;
30 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

7. The compound of Claim 6 wherein R¹ is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R² is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl;

5 or
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

8. The compound of Claim 7 selected from the group consisting of
10 6-benzyl-3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one;
6-benzyl-3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one; and
15 3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2,2-trifluoro-ethyl)-2,6-dihydro-pyrazolo[3,4-d]pyridazin-7-one;
a pharmaceutically acceptable solvate or hydrate of said compound.

9. The compound of Claim 1 wherein said compound is a compound of Formula (II); a pharmaceutically acceptable salt thereof, or a solvate or
20 hydrate of said compound or said salt.

10. The compound of Claim 9 wherein
R³ is hydrogen or (C₁-C₄)alkyl optionally substituted with one or more fluorines; and
25 R⁴ is a chemical moiety selected from (C₁-C₉)alkyl, aryl(C₁-C₅)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring, or 3- to 6-membered partially or fully saturated heterocyclic ring, where the chemical moiety is optionally substituted with one or more substituents;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
30 said compound or said salt.

11. The compound of Claim 10 wherein
R³ is hydrogen or methyl;
R⁴ is fluoro-substituted (C₁-C₅)alkyl, aryl(C₁-C₅)alkyl, cyclopentyl,
cyclohexyl, pyranyl, furanyl, pyrrolidinyl, or piperidinyl;
5 a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
said compound or said salt.

12. The compound of Claim 9, 10, or 11 wherein R¹ and R² are each
independently a phenyl substituted with 1 to 3 substituents independently
10 selected from the group consisting of halo, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, halo-
substituted (C₁-C₄)alkyl, and cyano;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
said compound or said salt.

15 13. The compound of Claim 12 wherein R¹ and R² are each
independently a phenyl substituted with 1 to 2 substituents independently
selected from the group consisting of chloro, fluoro, (C₁-C₄)alkoxy, (C₁-
C₄)alkyl, fluoro-substituted (C₁-C₄)alkyl, and cyano;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
20 said compound or said salt.

14. The compound of Claim 13 wherein R¹ is 2-chlorophenyl, 2-
fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-
fluorophenyl, or 2,4-difluorophenyl; and R² is 4-chlorophenyl, 4-cyanophenyl,
25 or 4-fluorophenyl;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of
said compound or said salt.

15. The compound of Claim 14 selected from the group consisting
30 of

1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one;
2-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-5-ethyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one;
5 2-(4-chloro-phenyl)-1-(2-chloro-phenyl)-5-cyclohexyl-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one; and
5-benzyl-2-(4-chloro-phenyl)-1-(2-chloro-phenyl)-1,5-dihydro-imidazo[4,5-d]pyridazin-4-one
a pharmaceutically acceptable solvate or hydrate of said compound.

10

16. A pharmaceutical composition comprising (1) a compound of any one of the preceding Claims, or a solvate or hydrate of said compound; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

15

17. The composition of Claim 23 further comprising at least one additional pharmaceutical agent selected from the group consisting of a nicotine receptor partial agonist, an opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent.

20

18. A method for treating a disease, condition or disorder which is modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of any one of Claims 1 through 15;

25

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

30

19. The method of Claim 18 wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is selected from the group consisting of weight loss, obesity, bulimia, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, alcoholism, tobacco

abuse, dementia, seizure disorders, epilepsy, attention deficit disorder, Parkinson's disease, inflammation, gastrointestinal disorders, and type II diabetes.

- 5 20. The use of a compound of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 in the manufacture of a medicament for treating a disease, condition or disorder which is modulated by a cannabinoid receptor antagonist.

INTERNATIONAL SEARCH REPORT

International Application No PCT/IB2004/004017

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D487/04 A61K31/4985 A61P25/00 //(C07D487/04,237:00,231:00),(C07D487/04,237:00,235:00)
--

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 656 171 A (AUSTEL ET AL) 7 April 1987 (1987-04-07) examples 11-18 -----	1-20
A	US 3 244 715 A (CASTLE RAYMOND N) 5 April 1966 (1966-04-05) claims 1-10 -----	1-20
A	PALMER S L ET AL: "Review: Cannabinergic ligands" CHEMISTRY AND PHYSICS OF LIPIDS, LIMERICK, IR, vol. 121, 2002, pages 3-19, XP002977255 ISSN: 0009-3084 the whole document ----- -/-	1-20

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 February 2005

Date of mailing of the international search report
--

07.03.05

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-9016
--

Authorized officer

Goss, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB2004/004017

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GOYA P ET AL: "RECENT ADVANCES IN CANNABINOID RECEPTOR AGONISTS AND ANTAGONISTS" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 10, 2000, pages 1529-1538, XP001036546 ISSN: 1354-3776 page 1530 - page 1536 -----	1-20
A	BARTH F: "Cannabinoid receptor agonists and antagonists" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 3, March 1998 (1998-03), pages 301-313, XP002150850 ISSN: 1354-3776 page 302 - page 309 -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2004/004017

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 18 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members			International Application No PCT/IB2004/004017	
Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 4656171	A 07-04-1987	DE 3346640 A1 AU 571296 B2 AU 3704484 A DD 234012 A5 DK 610084 A EP 0148438 A2 ES 8600297 A1 ES 8603890 A1 ES 8603891 A1 ES 8603892 A1 FI 845086 A GR 82559 A1 HU 36794 A2 JP 60169480 A NO 845170 A NZ 210653 A PT 79739 A ,B US 4746658 A ZA 8409971 A	04-07-1985 14-04-1988 04-07-1985 19-03-1986 24-06-1985 17-07-1985 01-01-1986 16-05-1986 16-05-1986 16-05-1986 24-06-1985 23-04-1985 28-10-1985 02-09-1985 24-06-1985 12-02-1988 01-01-1985 24-05-1988 27-08-1986	
US 3244715	A 05-04-1966	NONE		

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)